[sentNum: 1]<Annotation Id="6371" Type="Sentence" StartNode="0" EndNode="88">Screening for Cancer: Advice for High-Value Care From the American College of PhysiciansPreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:care activity SemanticType:[acty] PreferredName:American College of Physicians SemanticType:[prog] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Advice SemanticType:[hlca] POS:VBG POS:IN POS:NN POS:: POS:NNP POS:IN POS:NNP POS:NNP POS:NNP POS:IN POS:DT POS:NNP POS:NNP POS:IN POS:NNP 
[sentNum: 2]<Annotation Id="6372" Type="Sentence" StartNode="90" EndNode="192">Background: Cancer screening is one approach to reducing cancer-related morbidity and mortality rates. PreferredName:Background SemanticType:[cnce] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:One SemanticType:[qnco] PreferredName:Approach SemanticType:[spco] PreferredName:Reduced SemanticType:[qlco] PreferredName:Related to Cancer SemanticType:[fndg] PreferredName:Morbidity - disease rate SemanticType:[qnco] PreferredName:Death Rate SemanticType:[qnco] POS:NN POS:: POS:NNP POS:NN POS:VBZ POS:CD POS:NN POS:TO POS:VBG POS:JJ POS:NN POS:CC POS:NN POS:NNS POS:. 
[sentNum: 3]<Annotation Id="6373" Type="Sentence" StartNode="193" EndNode="232">Screening strategies vary in intensity. PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:strategy SemanticType:[menp] PreferredName:With intensity SemanticType:[qlco] POS:NN POS:NNS POS:VBP POS:IN POS:NN POS:. 
[sentNum: 4]<Annotation Id="6374" Type="Sentence" StartNode="233" EndNode="294">Higher-intensity strategies are not necessarily higher value. PreferredName:Abnormally high SemanticType:[qlco] PreferredName:With intensity SemanticType:[qlco] PreferredName:strategy SemanticType:[menp] PreferredName:Negation SemanticType:[ftcn] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] POS:JJ POS:NNS POS:VBP POS:RB POS:RB POS:JJR POS:NN POS:. 
[sentNum: 5]<Annotation Id="6375" Type="Sentence" StartNode="295" EndNode="482">High-value strategies provide a degree of benefits that clearly justifies the harms and costs incurred; low-value screening provides limited or no benefits to justify the harms and costs. PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:strategy SemanticType:[menp] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:Benefits SemanticType:[qnco] PreferredName:justify SemanticType:[ftcn] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Limited (extensiveness) SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:justify SemanticType:[ftcn] PreferredName:Financial cost SemanticType:[qnco] POS:JJ POS:NNS POS:VBP POS:DT POS:NN POS:IN POS:NNS POS:WDT POS:RB POS:VBZ POS:DT POS:NNS POS:CC POS:NNS POS:VBN POS:: POS:JJ POS:NN POS:VBZ POS:JJ POS:CC POS:DT POS:NNS POS:TO POS:VB POS:DT POS:NNS POS:CC POS:NNS POS:. 
[sentNum: 6]<Annotation Id="6376" Type="Sentence" StartNode="483" EndNode="574">When cancer screening leads to benefits, an optimal intensity of screening maximizes value. PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Dietary Lead SemanticType:[elii] PreferredName:Benefits SemanticType:[qnco] PreferredName:Optimum SemanticType:[qlco] PreferredName:With intensity SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Numerical value SemanticType:[qnco] POS:WRB POS:NN POS:NN POS:VBZ POS:TO POS:NNS POS:, POS:DT POS:JJ POS:NN POS:IN POS:NN POS:VBZ POS:NN POS:. 
[sentNum: 7]<Annotation Id="6377" Type="Sentence" StartNode="575" EndNode="659">Some aspects of screening practices, especially overuse and underuse, are low value.PreferredName:Some (qualifier value) SemanticType:[qnco] PreferredName:Aspect (characteristic) SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Practice Experience SemanticType:[menp] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] POS:DT POS:NNS POS:IN POS:JJ POS:NNS POS:, POS:RB POS:NN POS:CC POS:NN POS:, POS:VBP POS:JJ POS:NN POS:. 
[sentNum: 8]<Annotation Id="6378" Type="Sentence" StartNode="663" EndNode="1111">Methods: Screening strategies for asymptomatic, average-risk adults for 5 common types of cancer were evaluated by reviewing clinical guidelines and evidence syntheses from the American College of Physicians (ACP), U.S. Preventive Services Task Force, American Academy of Family Physicians, American Cancer Society, American Congress of Obstetricians and Gynecologists, American Gastroenterological Association, and American Urological Association. PreferredName:Methods SemanticType:[inpr] PreferredName:strategy SemanticType:[menp] PreferredName:Asymptomatic screening SemanticType:[hlca] PreferredName:Average SemanticType:[qnco] PreferredName:Risk SemanticType:[qlco] PreferredName:Adult SemanticType:[aggp] PreferredName:Preposition For SemanticType:[qlco] PreferredName:shared attribute SemanticType:[ftcn] PreferredName:Type 5 SemanticType:[inpr] PreferredName:Malignant Neoplasms SemanticType:[neop] PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Reviewing SemanticType:[qlco] PreferredName:Clinical SemanticType:[qlco] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Anabolism SemanticType:[biof] PreferredName:American College of Physicians SemanticType:[prog] PreferredName:United States SemanticType:[geoa] PreferredName:Preventive service healthcare SemanticType:[hlca] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:American SemanticType:[popg] PreferredName:Academies SemanticType:[orgt] PreferredName:Physicians, Family SemanticType:[prog] PreferredName:American Cancer Society SemanticType:[pros] PreferredName:American SemanticType:[popg] PreferredName:Congress (U.S. Legislature) SemanticType:[orgt] PreferredName:Obstetrician SemanticType:[prog] PreferredName:Gynecologist SemanticType:[prog] PreferredName:American SemanticType:[popg] PreferredName:gastroenterology (field) SemanticType:[bmod] PreferredName:Mental association SemanticType:[menp] PreferredName:American SemanticType:[popg] PreferredName:Mental association SemanticType:[menp] POS:NNS POS:: POS:NN POS:NNS POS:IN POS:JJ POS:, POS:JJ POS:NNS POS:IN POS:CD POS:JJ POS:NNS POS:IN POS:NN POS:VBD POS:VBN POS:IN POS:VBG POS:JJ POS:NNS POS:CC POS:NN POS:NNS POS:IN POS:DT POS:NNP POS:NNP POS:IN POS:NNP POS:CD POS:NNP POS:CD POS:, POS:NNP POS:. POS:NN POS:. POS:NNP POS:NNPS POS:NNP POS:NNP POS:, POS:NNP POS:NNP POS:IN POS:NNP POS:NNP POS:, POS:NNP POS:NNP POS:NNP POS:, POS:NNP POS:NNP POS:IN POS:NNPS POS:CC POS:NNPS POS:, POS:NNP POS:NNP POS:NNP POS:, POS:CC POS:JJ POS:NNP POS:NNP POS:. 
[sentNum: 9]<Annotation Id="6379" Type="Sentence" StartNode="1112" EndNode="1356">&#x201c;High value&#x201d; was defined as the lowest screening intensity threshold at which organizations agree about screening recommendations for each type of cancer and &#x201c;low value&#x201d; as agreement about not recommending overly intensive screening strategies. PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Definition SemanticType:[cnce] PreferredName:Lowest SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:With intensity SemanticType:[qlco] PreferredName:Threshold SemanticType:[qlco] PreferredName:Organization administrative structures SemanticType:[orgt] PreferredName:Agree SemanticType:[inpr] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Type - attribute SemanticType:[qlco] PreferredName:Malignant Neoplasms SemanticType:[neop] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Agreement SemanticType:[socb] PreferredName:Negation SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:strategy SemanticType:[menp] POS:NN POS:JJ POS:NN POS:NN POS:VBD POS:VBN POS:IN POS:DT POS:JJS POS:NN POS:NN POS:NN POS:IN POS:WDT POS:NNS POS:VBP POS:IN POS:JJ POS:NNS POS:IN POS:DT POS:NN POS:IN POS:NN POS:CC POS:RB POS:JJ POS:NN POS:NN POS:IN POS:NN POS:IN POS:RB POS:VBG POS:RB POS:JJ POS:NN POS:NNS POS:. 
[sentNum: 10]<Annotation Id="6380" Type="Sentence" StartNode="1357" EndNode="1604">This information is supplemented with additional findings from randomized, controlled trials; modeling studies; and studies of costs or resource use, including information found in the National Cancer Institute's Physician Data Query and UpToDate.PreferredName:Information SemanticType:[idcn] PreferredName:Dietary Supplements SemanticType:[food] PreferredName:Additional SemanticType:[ftcn] PreferredName:Procedure findings:Finding:Point in time:^Patient:Narrative SemanticType:[clna] PreferredName:Randomized Controlled Trials as Topic SemanticType:[inpr, resa] PreferredName:Modeling SemanticType:[inpr, resa] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Resources SemanticType:[idcn] PreferredName:utilization qualifier SemanticType:[ftcn] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Information SemanticType:[idcn] PreferredName:Present SemanticType:[qnco] PreferredName:National Cancer Institute SemanticType:[hcro] PreferredName:PDQ (Physician Data Query) SemanticType:[inpr] POS:DT POS:NN POS:VBZ POS:VBN POS:IN POS:JJ POS:NNS POS:IN POS:VBN POS:, POS:VBN POS:NNS POS:: POS:NN POS:NNS POS:: POS:CC POS:NNS POS:IN POS:NNS POS:CC POS:NN POS:NN POS:, POS:VBG POS:NN POS:VBN POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:POS POS:NNP POS:NNP POS:NNP POS:CC POS:NNP POS:. 
[sentNum: 11]<Annotation Id="6381" Type="Sentence" StartNode="1608" EndNode="1689">Cancer is a major health problem in the United States, causing 1 in 4 deaths (1). PreferredName:Malignant Neoplasms SemanticType:[neop] PreferredName:Major SemanticType:[qlco] PreferredName:Health SemanticType:[idcn] PreferredName:Problem SemanticType:[fndg] PreferredName:United States SemanticType:[geoa] PreferredName:Causing SemanticType:[ftcn] PreferredName:1+ Score SemanticType:[qnco] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:1+ Score SemanticType:[qnco] POS:NN POS:VBZ POS:DT POS:JJ POS:NN POS:NN POS:IN POS:DT POS:NNP POS:NNPS POS:, POS:VBG POS:CD POS:IN POS:CD POS:NNS POS:VBP POS:CD POS:CD POS:. 
[sentNum: 12]<Annotation Id="6382" Type="Sentence" StartNode="1690" EndNode="1765">One approach to reducing cancer morbidity and mortality rates is screening. PreferredName:One SemanticType:[qnco] PreferredName:Approach SemanticType:[spco] PreferredName:Reduced SemanticType:[qlco] PreferredName:Malignant Neoplasms SemanticType:[neop] PreferredName:Morbidity - disease rate SemanticType:[qnco] PreferredName:Death Rate SemanticType:[qnco] PreferredName:Aspects of disease screening SemanticType:[ftcn] POS:CD POS:NN POS:TO POS:VBG POS:NN POS:NN POS:CC POS:NN POS:NNS POS:VBZ POS:VBG POS:. 
[sentNum: 13]<Annotation Id="6383" Type="Sentence" StartNode="1766" EndNode="1868">However, even full implementation of effective screening strategies would not eliminate cancer deaths.PreferredName:Full SemanticType:[qlco] PreferredName:Implementation SemanticType:[acty] PreferredName:Effectiveness SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:strategy SemanticType:[menp] PreferredName:Negation SemanticType:[ftcn] PreferredName:Malignant Neoplasms SemanticType:[neop] PreferredName:Cessation of life SemanticType:[orgf] POS:RB POS:, POS:RB POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:NNS POS:MD POS:RB POS:VB POS:NN POS:NNS POS:. 
[sentNum: 14]<Annotation Id="6384" Type="Sentence" StartNode="1872" EndNode="1930">Screening strategies vary in what we call &#x201c;intensity&#x201d; (2). PreferredName:Disease Screening SemanticType:[diap] PreferredName:strategy SemanticType:[menp] PreferredName:Decision SemanticType:[menp] PreferredName:With intensity SemanticType:[qlco] PreferredName:2+ Score SemanticType:[qnco] POS:NN POS:NNS POS:VBP POS:IN POS:WP POS:PRP POS:VBP POS:RB POS:NN POS:CD POS:NN POS:CD POS:NN POS:. 
[sentNum: 15]<Annotation Id="6385" Type="Sentence" StartNode="1931" EndNode="2041">Higher-intensity strategies screen broader populations more frequently or with more sensitive screening tests. PreferredName:Abnormally high SemanticType:[qlco] PreferredName:With intensity SemanticType:[qlco] PreferredName:strategy SemanticType:[menp] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Widening SemanticType:[spco] PreferredName:Population Group SemanticType:[popg] PreferredName:Frequent SemanticType:[tmco] PreferredName:Confidentiality - sensitive SemanticType:[idcn] PreferredName:Screening Tests SemanticType:[hlca] POS:JJ POS:NNS POS:NN POS:JJR POS:NNS POS:RBR POS:RB POS:CC POS:IN POS:RBR POS:JJ POS:NN POS:NNS POS:. 
[sentNum: 16]<Annotation Id="6386" Type="Sentence" StartNode="2042" EndNode="2082">Screening strategies also vary in value. PreferredName:Disease Screening SemanticType:[diap] PreferredName:strategy SemanticType:[menp] PreferredName:Numerical value SemanticType:[qnco] POS:NN POS:NNS POS:RB POS:VBP POS:IN POS:NN POS:. 
[sentNum: 17]<Annotation Id="6387" Type="Sentence" StartNode="2083" EndNode="2229">As defined by the American College of Physicians (ACP) (3&#x2013;5), value is determined by an intervention's health benefits versus its harms and costs. PreferredName:Definition SemanticType:[cnce] PreferredName:American College of Physicians SemanticType:[prog] PreferredName:3/5 SemanticType:[qnco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Intervention regimes SemanticType:[hlca] PreferredName:Health Benefits SemanticType:[qnco] PreferredName:Financial cost SemanticType:[qnco] POS:IN POS:VBN POS:IN POS:DT POS:NNP POS:NNP POS:IN POS:NNP POS:CD POS:NNP POS:CD POS:CD POS:CD POS:NN POS:CD POS:NN POS:, POS:NN POS:VBZ POS:VBN POS:IN POS:DT POS:NN POS:POS POS:NN POS:NNS POS:CC POS:PRP$ POS:NNS POS:CC POS:NNS POS:. 
[sentNum: 18]<Annotation Id="6388" Type="Sentence" StartNode="2230" EndNode="2401">High-value strategies return large health benefits for the harms and costs incurred; low-value strategies return disproportionately small benefits for the harms and costs. PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:strategy SemanticType:[menp] PreferredName:Return to SemanticType:[qlco] PreferredName:Large SemanticType:[qnco] PreferredName:Health SemanticType:[idcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:strategy SemanticType:[menp] PreferredName:Return to SemanticType:[qlco] PreferredName:Small SemanticType:[qnco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Financial cost SemanticType:[qnco] POS:JJ POS:NNS POS:VB POS:JJ POS:NN POS:NNS POS:IN POS:DT POS:NNS POS:CC POS:NNS POS:VBN POS:: POS:JJ POS:NNS POS:VBP POS:RB POS:JJ POS:NNS POS:IN POS:DT POS:NNS POS:CC POS:NNS POS:. 
[sentNum: 19]<Annotation Id="6389" Type="Sentence" StartNode="2402" EndNode="2576">Although highintensity strategies aim to maximize cancer detection, value is optimized by finding the level of intensity that best balances benefits with harms and costs (2).PreferredName:strategy SemanticType:[menp] PreferredName:Aim (idea) SemanticType:[idcn] PreferredName:To SemanticType:[qlco] PreferredName:Cancer Detection SemanticType:[hlca] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Experimental Finding SemanticType:[fndg] PreferredName:Levels (qualifier value) SemanticType:[qlco] PreferredName:With intensity SemanticType:[qlco] PreferredName:best (quality) SemanticType:[qlco] PreferredName:Does balance SemanticType:[fndg] PreferredName:Benefits SemanticType:[qnco] PreferredName:Financial cost SemanticType:[qnco] PreferredName:2+ Score SemanticType:[qnco] POS:IN POS:NN POS:NNS POS:VBP POS:TO POS:VB POS:NN POS:NN POS:, POS:NN POS:VBZ POS:VBN POS:IN POS:VBG POS:DT POS:NN POS:IN POS:NN POS:WDT POS:JJS POS:NNS POS:NNS POS:IN POS:NNS POS:CC POS:NNS POS:VBP POS:CD POS:CD POS:. 
[sentNum: 20]<Annotation Id="6390" Type="Sentence" StartNode="2580" EndNode="2711">Regardless of value, cancer screening is popular among the U.S. public and is done more frequently than in other countries (6 &#x2013; 8). PreferredName:Numerical value SemanticType:[qnco] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:popularity SemanticType:[socb] PreferredName:United States SemanticType:[geoa] PreferredName:More SemanticType:[ftcn] PreferredName:Frequent SemanticType:[tmco] PreferredName:Country SemanticType:[geoa] POS:RB POS:IN POS:NN POS:, POS:NN POS:NN POS:VBZ POS:JJ POS:IN POS:DT POS:NNP POS:. POS:NN POS:. POS:JJ POS:CC POS:VBZ POS:VBN POS:RBR POS:RB POS:IN POS:IN POS:JJ POS:NNS POS:VBP POS:CD POS:CD POS:CD POS:NN POS:. 
[sentNum: 21]<Annotation Id="6391" Type="Sentence" StartNode="2712" EndNode="2800">Some aspects of our screening practices, especially overuse and underuse, are low value. PreferredName:Some (qualifier value) SemanticType:[qnco] PreferredName:Aspect (characteristic) SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Practice Experience SemanticType:[menp] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] POS:DT POS:NNS POS:IN POS:PRP$ POS:JJ POS:NNS POS:, POS:RB POS:NN POS:CC POS:NN POS:, POS:VBP POS:JJ POS:NN POS:. 
[sentNum: 22]<Annotation Id="6392" Type="Sentence" StartNode="2801" EndNode="3025">A screening program is considered low value when persons in whom the benefits clearly outweigh the harms and costs are not being screened intensively enough (9, 10) or when persons are being screened overly intensively (11).PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Program SemanticType:[phsu] PreferredName:consider SemanticType:[idcn] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Persons SemanticType:[popg] PreferredName:Benefits SemanticType:[qnco] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Persons SemanticType:[popg] PreferredName:Screening - procedure intent SemanticType:[ftcn] POS:DT POS:JJ POS:NN POS:VBZ POS:VBN POS:JJ POS:NN POS:WRB POS:NNS POS:IN POS:WP POS:DT POS:NNS POS:RB POS:VBP POS:DT POS:NNS POS:CC POS:NNS POS:VBP POS:RB POS:VBG POS:VBN POS:RB POS:RB POS:CD POS:CD POS:, POS:CD POS:CD POS:CC POS:WRB POS:NNS POS:VBP POS:VBG POS:VBN POS:RB POS:RB POS:CD POS:CD POS:NN POS:. 
[sentNum: 23]<Annotation Id="6393" Type="Sentence" StartNode="3029" EndNode="3357">Improving cancer screening value requires overcoming 3 main challenges: increasing access to highvalue screening for populations without adequate access to care; increasing high-value screening in persons with adequate care access; and reducing use of low-value screening strategies in everyone, with or without adequate access. PreferredName:Improving (qualifier value) SemanticType:[qlco] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Overcome SemanticType:[acty] PreferredName:Main SemanticType:[qlco] PreferredName:Challenge SemanticType:[hlca] PreferredName:Increasing SemanticType:[ftcn] PreferredName:Role Class - access SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Population Group SemanticType:[popg] PreferredName:Sufficient SemanticType:[qlco] PreferredName:Role Class - access SemanticType:[idcn] PreferredName:care activity SemanticType:[acty] PreferredName:Increasing SemanticType:[ftcn] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Persons SemanticType:[popg] PreferredName:Sufficient SemanticType:[qlco] PreferredName:care activity SemanticType:[acty] PreferredName:Role Class - access SemanticType:[idcn] PreferredName:Reduced SemanticType:[qlco] PreferredName:Use of SemanticType:[ftcn] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:strategy SemanticType:[menp] PreferredName:Sufficient SemanticType:[qlco] PreferredName:Role Class - access SemanticType:[idcn] POS:NN POS:NN POS:NN POS:NN POS:VBZ POS:VBG POS:CD POS:JJ POS:NNS POS:: POS:VBG POS:NN POS:TO POS:JJ POS:NN POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:TO POS:VB POS:: POS:VBG POS:JJ POS:NN POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:NN POS:: POS:CC POS:VBG POS:NN POS:IN POS:JJ POS:NN POS:NNS POS:IN POS:NN POS:, POS:IN POS:CC POS:IN POS:JJ POS:NN POS:. 
[sentNum: 24]<Annotation Id="6394" Type="Sentence" StartNode="3358" EndNode="3406">This article focuses on the latter 2 challenges. PreferredName:Article SemanticType:[inpr] PreferredName:Focal SemanticType:[spco] PreferredName:Challenge SemanticType:[hlca] POS:DT POS:NN POS:VBZ POS:IN POS:DT POS:JJ POS:CD POS:NNS POS:. 
[sentNum: 25]<Annotation Id="6395" Type="Sentence" StartNode="3407" EndNode="3528">It is the second of 2 papers commissioned by the ACP to define and encourage high-value, cost-conscious cancer screening. PreferredName:second (number) SemanticType:[qnco] PreferredName:Paper SemanticType:[mnob] PreferredName:Cerebral Palsy, Ataxic, Autosomal Recessive SemanticType:[dsyn] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Conscious SemanticType:[menp] PreferredName:Screening for cancer SemanticType:[diap] POS:PRP POS:VBZ POS:DT POS:NN POS:IN POS:CD POS:NNS POS:VBN POS:IN POS:DT POS:NN POS:TO POS:VB POS:CC POS:VB POS:JJ POS:, POS:JJ POS:NN POS:NN POS:. 
[sentNum: 26]<Annotation Id="6396" Type="Sentence" StartNode="3529" EndNode="3806">We note agreement among various organizations on the lowest-intensity screening threshold recommended for &#x201c;average-risk individuals&#x201d; for each type of cancer (high value) and whether they recommend against or do not recommend for more intensive screening strategies (low value). PreferredName:Note (document) SemanticType:[inpr] PreferredName:Agreement SemanticType:[socb] PreferredName:Various patch test substance SemanticType:[irda] PreferredName:Organization administrative structures SemanticType:[orgt] PreferredName:Lowest SemanticType:[qlco] PreferredName:With intensity SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Threshold SemanticType:[qlco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Average SemanticType:[qnco] PreferredName:Risk SemanticType:[qlco] PreferredName:Persons SemanticType:[popg] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Type - attribute SemanticType:[qlco] PreferredName:Malignant Neoplasms SemanticType:[neop] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:strategy SemanticType:[menp] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] POS:PRP POS:VBP POS:NN POS:IN POS:JJ POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:NN POS:VBD POS:IN POS:CD POS:JJ POS:NNS POS:VBP POS:IN POS:DT POS:NN POS:IN POS:NN POS:CD POS:JJ POS:NN POS:NN POS:CC POS:IN POS:PRP POS:VBP POS:IN POS:CC POS:VB POS:RB POS:VB POS:IN POS:JJR POS:JJ POS:NN POS:NNS POS:RB POS:JJ POS:NN POS:NN POS:. 
[sentNum: 27]<Annotation Id="6397" Type="Sentence" StartNode="3807" EndNode="4006">We provide information on use of overly intensive, low-value screening and end with evidence suggesting future directions to reduce overly intensive screening that may enhance cancer screening value.PreferredName:Providing (action) SemanticType:[acty] PreferredName:Information SemanticType:[idcn] PreferredName:Use of SemanticType:[ftcn] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Stop (qualifier value) SemanticType:[tmco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:suggestion SemanticType:[idcn] PreferredName:Future SemanticType:[tmco] PreferredName:Directions SemanticType:[spco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Numerical value SemanticType:[qnco] POS:PRP POS:VBP POS:NN POS:IN POS:NN POS:IN POS:RB POS:JJ POS:, POS:JJ POS:NN POS:CC POS:NN POS:IN POS:NN POS:VBG POS:JJ POS:NNS POS:TO POS:VB POS:RB POS:JJ POS:NN POS:WDT POS:MD POS:VB POS:NN POS:NN POS:NN POS:. 
[sentNum: 28]<Annotation Id="6398" Type="Sentence" StartNode="4010" EndNode="4017">METHODS PreferredName:Methods aspects SemanticType:[inpr] POS:NNS 
[sentNum: 29]<Annotation Id="6399" Type="Sentence" StartNode="4020" EndNode="4112">We focused on 5 common types of cancer: breast, cervical, colorectal, ovarian, and prostate. PreferredName:Has focus SemanticType:[ftcn] PreferredName:shared attribute SemanticType:[ftcn] PreferredName:Type 5 SemanticType:[inpr] PreferredName:Malignant Neoplasms SemanticType:[neop] PreferredName:Breast SemanticType:[bpoc] PreferredName:Cervical SemanticType:[spco] PreferredName:Colorectal SemanticType:[spco] PreferredName:Ovaro- SemanticType:[bpoc] PreferredName:Prostate SemanticType:[bpoc] POS:PRP POS:VBD POS:IN POS:CD POS:JJ POS:NNS POS:IN POS:NN POS:: POS:NN POS:, POS:JJ POS:, POS:JJ POS:, POS:JJ POS:, POS:CC POS:NN POS:. 
[sentNum: 30]<Annotation Id="6400" Type="Sentence" StartNode="4113" EndNode="4192">This article is intended to provide advice rather than to serve as a guideline. PreferredName:Article SemanticType:[inpr] PreferredName:intent SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Advice SemanticType:[hlca] PreferredName:To SemanticType:[qlco] PreferredName:Guideline [Publication Type] SemanticType:[inpr] POS:DT POS:NN POS:VBZ POS:VBN POS:TO POS:VB POS:NN POS:RB POS:IN POS:TO POS:VB POS:IN POS:DT POS:NN POS:. 
[sentNum: 31]<Annotation Id="6401" Type="Sentence" StartNode="4193" EndNode="4553">It is based on a narrative review of clinical guidelines and evidence syntheses from the American College of Physicians (ACP), U.S. Preventive Services Task Force, American Cancer Society, American Academy of Family Physicians, American Congress of Obstetricians and Gynecologists, American Urological Association, and American Gastroenterological Association. PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:narrative review SemanticType:[inpr] PreferredName:Clinical SemanticType:[qlco] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Anabolism SemanticType:[biof] PreferredName:American College of Physicians SemanticType:[prog] PreferredName:United States SemanticType:[geoa] PreferredName:Preventive service healthcare SemanticType:[hlca] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:American Cancer Society SemanticType:[pros] PreferredName:American SemanticType:[popg] PreferredName:Academies SemanticType:[orgt] PreferredName:Physicians, Family SemanticType:[prog] PreferredName:American SemanticType:[popg] PreferredName:Congress (U.S. Legislature) SemanticType:[orgt] PreferredName:Obstetrician SemanticType:[prog] PreferredName:Gynecologist SemanticType:[prog] PreferredName:American SemanticType:[popg] PreferredName:Relationship by association SemanticType:[socb] PreferredName:American SemanticType:[popg] PreferredName:gastroenterology (field) SemanticType:[bmod] PreferredName:Relationship by association SemanticType:[socb] POS:PRP POS:VBZ POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:IN POS:JJ POS:NNS POS:CC POS:NN POS:NNS POS:IN POS:DT POS:NNP POS:NNP POS:IN POS:NNP POS:CD POS:NNP POS:CD POS:, POS:NNP POS:. POS:NN POS:. POS:NNP POS:NNPS POS:NNP POS:NNP POS:, POS:NNP POS:NNP POS:NNP POS:, POS:NNP POS:NNP POS:IN POS:NNP POS:NNP POS:, POS:NNP POS:NNP POS:IN POS:NNPS POS:CC POS:NNPS POS:, POS:NNP POS:NNP POS:NNP POS:, POS:CC POS:JJ POS:NNP POS:NNP POS:. 
[sentNum: 32]<Annotation Id="6402" Type="Sentence" StartNode="4554" EndNode="5041">Because these organizations usually do not estimate costs in their recommendations, we searched the National Cancer Institute's Physician Data Query system, UpToDate, and modeling studies from the National Cancer Institute's Cancer Intervention and Surveillance Modeling Network for additional evidence from randomized, controlled trials (RCTs) or models of screening effectiveness, as well as national studies of the costs of various screening strategies for our target types of cancer. PreferredName:Organization administrative structures SemanticType:[orgt] PreferredName:Negation SemanticType:[ftcn] PreferredName:Estimated SemanticType:[qnco] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Search - action SemanticType:[acty] PreferredName:National Cancer Institute SemanticType:[hcro] PreferredName:PDQ (Physician Data Query) SemanticType:[inpr] PreferredName:Entity Code - System SemanticType:[mnob] PreferredName:Modeling SemanticType:[inpr, resa] PreferredName:National Cancer Institute SemanticType:[hcro] PreferredName:Intervention Studies SemanticType:[resa] PreferredName:Surveillance Modeling SemanticType:[resa] PreferredName:Consortium or Network SemanticType:[prog] PreferredName:Additional SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Randomized Controlled Trials as Topic SemanticType:[inpr, resa] PreferredName:Model SemanticType:[inpr] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Effectiveness SemanticType:[qlco] PreferredName:National citizen SemanticType:[inpr] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Various patch test substance SemanticType:[irda] PreferredName:Screening Study SemanticType:[resa] PreferredName:strategy SemanticType:[menp] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Target SemanticType:[ftcn] PreferredName:Type - attribute SemanticType:[qlco] PreferredName:Malignant Neoplasms SemanticType:[neop] POS:IN POS:DT POS:NNS POS:RB POS:VBP POS:RB POS:VB POS:NNS POS:IN POS:PRP$ POS:NNS POS:, POS:PRP POS:VBD POS:DT POS:NNP POS:NNP POS:NNP POS:POS POS:NNP POS:NNP POS:NNP POS:NN POS:, POS:NNP POS:, POS:CC POS:NN POS:NNS POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:POS POS:NN POS:NN POS:CC POS:NNP POS:NNP POS:NNP POS:IN POS:JJ POS:NN POS:IN POS:VBN POS:, POS:VBN POS:NNS POS:VBP POS:NNS POS:CD POS:CC POS:NNS POS:IN POS:VBG POS:NN POS:, POS:RB POS:RB POS:IN POS:JJ POS:NNS POS:IN POS:DT POS:NNS POS:IN POS:JJ POS:JJ POS:NNS POS:IN POS:PRP$ POS:NN POS:NNS POS:IN POS:NN POS:. 
[sentNum: 33]<Annotation Id="6403" Type="Sentence" StartNode="5042" EndNode="5538">We searched MEDLINE for articles about the costs and resource use of cancer screening published within the past 5 years (1 January 2009 to 30 June 2014) in the following medical journals: Annals of Internal Medicine, The Journal of the American Medical Association (JAMA), JAMA Internal Medicine, Journal of General Internal Medicine, The New England Journal of Medicine, BMJ, The Lancet, Journal of the National Cancer Institute, Obstetrics &amp; Gynecology, and CA: A Cancer Journal for Clinicians. PreferredName:Search - action SemanticType:[acty] PreferredName:MEDLINE SemanticType:[inpr] PreferredName:Article SemanticType:[inpr] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Resources SemanticType:[idcn] PreferredName:utilization qualifier SemanticType:[ftcn] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Scientific Publication SemanticType:[inpr] PreferredName:Past SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:1+ Score SemanticType:[qnco] PreferredName:Following SemanticType:[tmco] PreferredName:Medical SemanticType:[ftcn] PreferredName:Journal SemanticType:[inpr, mnob] PreferredName:Internal medicine physicians SemanticType:[inpr] PreferredName:Journal SemanticType:[inpr, mnob] PreferredName:American Medical Association SemanticType:[pros] PreferredName:Journal SemanticType:[inpr, mnob] PreferredName:American Medical Association SemanticType:[pros] PreferredName:Internal medicine physicians SemanticType:[inpr] PreferredName:Journal SemanticType:[inpr, mnob] PreferredName:general practice (field) SemanticType:[bmod] PreferredName:Internal - CodeSystemType SemanticType:[inpr] PreferredName:New England SemanticType:[geoa] PreferredName:Journal SemanticType:[inpr, mnob] PreferredName:Medicine SemanticType:[bmod] PreferredName:Lancet SemanticType:[medd] PreferredName:Journal of the National Cancer Institute SemanticType:[inpr] PreferredName:Physicians - Obstetrics &amp; Gynecology SemanticType:[prog] PreferredName:Malignant Neoplasms SemanticType:[neop] PreferredName:Journal SemanticType:[inpr, mnob] PreferredName:Clinician SemanticType:[prog] POS:PRP POS:VBD POS:NN POS:IN POS:NNS POS:IN POS:DT POS:NNS POS:CC POS:NN POS:NN POS:IN POS:NN POS:NN POS:VBN POS:IN POS:DT POS:JJ POS:CD POS:NNS POS:VBP POS:CD POS:NNP POS:CD POS:TO POS:CD POS:NNP POS:CD POS:CD POS:IN POS:DT POS:VBG POS:JJ POS:NNS POS:: POS:NNS POS:IN POS:JJ POS:NN POS:, POS:DT POS:NNP POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:NN POS:NN POS:CD POS:, POS:NNP POS:NNP POS:NNP POS:, POS:NNP POS:IN POS:NNP POS:NNP POS:NNP POS:, POS:DT POS:NNP POS:NNP POS:NNP POS:IN POS:NNP POS:, POS:NNP POS:, POS:DT POS:NNP POS:, POS:NNP POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:, POS:NNP POS:CC POS:NNP POS:, POS:CC POS:NNP POS:: POS:NNP POS:NNP POS:NNP POS:IN POS:NNS POS:. 
[sentNum: 34]<Annotation Id="6404" Type="Sentence" StartNode="5539" EndNode="5603">We examined reference lists of articles to find further studies.PreferredName:Examined SemanticType:[fndg] PreferredName:Reference Object SemanticType:[cnce] PreferredName:List SemanticType:[cnce] PreferredName:Article SemanticType:[inpr] PreferredName:Finding SemanticType:[fndg] PreferredName:Further SemanticType:[spco] PreferredName:Scientific Study SemanticType:[lbpr] POS:PRP POS:VBD POS:NN POS:NNS POS:IN POS:NNS POS:TO POS:VB POS:JJ POS:NNS POS:. 
[sentNum: 35]<Annotation Id="6405" Type="Sentence" StartNode="5607" EndNode="5855">For each type of cancer, we listed the least intensive screening strategies that all organizations recommend (defined as high-value care) and strategies that organizations either did not recommend or recommended against (defined as low-value care). PreferredName:Preposition For SemanticType:[qlco] PreferredName:Type - attribute SemanticType:[qlco] PreferredName:Malignant Neoplasms SemanticType:[neop] PreferredName:List SemanticType:[cnce] PreferredName:Less Than SemanticType:[inpr] PreferredName:Screening procedure SemanticType:[hlca] PreferredName:strategy SemanticType:[menp] PreferredName:Organization administrative structures SemanticType:[orgt] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Definition SemanticType:[cnce] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:care activity SemanticType:[acty] PreferredName:strategy SemanticType:[menp] PreferredName:Organization administrative structures SemanticType:[orgt] PreferredName:Negation SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Definition SemanticType:[cnce] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:care activity SemanticType:[acty] POS:IN POS:DT POS:NN POS:IN POS:NN POS:, POS:PRP POS:VBD POS:DT POS:JJS POS:JJ POS:NN POS:NNS POS:IN POS:DT POS:NNS POS:VBP POS:RB POS:VBN POS:IN POS:JJ POS:NN POS:NN POS:CC POS:NNS POS:WDT POS:NNS POS:CC POS:VBD POS:RB POS:VB POS:CC POS:VBN POS:IN POS:CD POS:VBN POS:IN POS:JJ POS:NN POS:NN POS:. 
[sentNum: 36]<Annotation Id="6406" Type="Sentence" StartNode="5856" EndNode="5931">The ACP used this information to develop high-value care advice statements. PreferredName:Cerebral Palsy, Ataxic, Autosomal Recessive SemanticType:[dsyn] PreferredName:Used by SemanticType:[fndg] PreferredName:Information SemanticType:[idcn] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:care activity SemanticType:[acty] PreferredName:Advice SemanticType:[hlca] PreferredName:Statement SemanticType:[idcn] POS:DT POS:NNP POS:VBD POS:DT POS:NN POS:TO POS:VB POS:JJ POS:NN POS:NN POS:NNS POS:. 
[sentNum: 37]<Annotation Id="6407" Type="Sentence" StartNode="5932" EndNode="6085">We used articles identified previously to suggest future directions that might enhance screening value by reducing overuse of overly intensive screening. PreferredName:Used by SemanticType:[fndg] PreferredName:Article SemanticType:[inpr] PreferredName:Identified SemanticType:[qlco] PreferredName:suggestion SemanticType:[idcn] PreferredName:Future SemanticType:[tmco] PreferredName:Directions SemanticType:[spco] PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Screening procedure SemanticType:[hlca] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Reduced SemanticType:[qlco] PreferredName:Screening procedure SemanticType:[hlca] POS:PRP POS:VBD POS:NNS POS:VBN POS:RB POS:TO POS:VB POS:JJ POS:NNS POS:WDT POS:MD POS:VB POS:JJ POS:NN POS:IN POS:VBG POS:NN POS:IN POS:RB POS:JJ POS:NN POS:. 
[sentNum: 38]<Annotation Id="6408" Type="Sentence" StartNode="6086" EndNode="6280">Although the ACP High Value Care Task Force does not include evidence about costs in its advice statements, cost is still an important part of the &#x201c;value framework&#x201d; developed by the authors (2). PreferredName:Cerebral Palsy, Ataxic, Autosomal Recessive SemanticType:[dsyn] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:care activity SemanticType:[acty] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:Negation SemanticType:[ftcn] PreferredName:Include (action) SemanticType:[acty] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Cost aspects SemanticType:[qnco] PreferredName:Advice SemanticType:[hlca] PreferredName:Statement SemanticType:[idcn] PreferredName:Cost aspects SemanticType:[qnco] PreferredName:Part of SemanticType:[spco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Journalist SemanticType:[prog] PreferredName:Integer +2 SemanticType:[qnco] POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:NNP POS:NNP POS:NNP POS:VBZ POS:RB POS:VBP POS:NN POS:IN POS:NNS POS:IN POS:PRP$ POS:NN POS:NNS POS:, POS:NN POS:VBZ POS:RB POS:DT POS:JJ POS:NN POS:IN POS:DT POS:NN POS:NN POS:NN POS:CD POS:VBN POS:IN POS:DT POS:NNS POS:VBP POS:CD POS:CD POS:. 
[sentNum: 39]<Annotation Id="6409" Type="Sentence" StartNode="6281" EndNode="6366">We provide examples from national studies about overuse of nonrecommended strategies.PreferredName:Providing (action) SemanticType:[acty] PreferredName:Example SemanticType:[cnce] PreferredName:National citizen SemanticType:[inpr] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:strategy SemanticType:[menp] POS:PRP POS:VBP POS:NNS POS:IN POS:JJ POS:NNS POS:IN POS:NN POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 40]<Annotation Id="6410" Type="Sentence" StartNode="6370" EndNode="6426">We focus on screening average-risk, asymptomatic adults. PreferredName:Has focus SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Average SemanticType:[qnco] PreferredName:Risk SemanticType:[qlco] PreferredName:Asymptomatic SemanticType:[fndg] PreferredName:Adult SemanticType:[aggp] POS:PRP POS:VBP POS:IN POS:NN POS:NN POS:, POS:JJ POS:NNS POS:. 
[sentNum: 41]<Annotation Id="6411" Type="Sentence" StartNode="6427" EndNode="6536">We do not address surveillance in patients with previous abnormal screening results or high-risk populations. PreferredName:Negation SemanticType:[ftcn] PreferredName:Address SemanticType:[spco] PreferredName:Medical Surveillance SemanticType:[hlca] PreferredName:Patients SemanticType:[podg] PreferredName:Previous SemanticType:[tmco] PreferredName:Abnormal result SemanticType:[fndg] PreferredName:Disease Screening SemanticType:[diap] PreferredName:High Risk Populations SemanticType:[popg] POS:PRP POS:VBP POS:RB POS:VB POS:NN POS:IN POS:NNS POS:IN POS:JJ POS:JJ POS:NN POS:NNS POS:CC POS:JJ POS:NNS POS:. 
[sentNum: 42]<Annotation Id="6412" Type="Sentence" StartNode="6537" EndNode="6793">Our understanding of factors, beyond patient age or a history of cancer in multiple family members or in an immediate family member at an early age, that have both clinically important effects on cancer risk and health outcomes due to screening is limited. PreferredName:Comprehension SemanticType:[menp] PreferredName:Factor SemanticType:[ftcn] PreferredName:Patients SemanticType:[podg] PreferredName:Age SemanticType:[orga] PreferredName:H/O: malignant neoplasm SemanticType:[fndg] PreferredName:Numerous SemanticType:[qnco] PreferredName:Family member SemanticType:[famg] PreferredName:Immediate family member SemanticType:[famg] PreferredName:Early SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:Both SemanticType:[qlco] PreferredName:Effect SemanticType:[qlco] PreferredName:Cancer Risk SemanticType:[qnco] PreferredName:Health Outcomes SemanticType:[inpr] PreferredName:Due to SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Limited (extensiveness) SemanticType:[ftcn] POS:PRP$ POS:NN POS:IN POS:NNS POS:, POS:IN POS:NN POS:NN POS:CC POS:DT POS:NN POS:IN POS:NN POS:IN POS:JJ POS:NN POS:NNS POS:CC POS:IN POS:DT POS:JJ POS:NN POS:NN POS:IN POS:DT POS:JJ POS:NN POS:, POS:WDT POS:VBP POS:DT POS:RB POS:JJ POS:NNS POS:IN POS:NN POS:NN POS:CC POS:NN POS:NNS POS:JJ POS:TO POS:NN POS:VBZ POS:VBN POS:. 
[sentNum: 43]<Annotation Id="6413" Type="Sentence" StartNode="6794" EndNode="6868">Value may differ for persons at higher or lower risk for cancer mortality. PreferredName:Numerical value SemanticType:[qnco] PreferredName:Persons SemanticType:[popg] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Low Risk SemanticType:[qnco] PreferredName:Cancer Death Rate SemanticType:[qnco] POS:NN POS:MD POS:VB POS:IN POS:NNS POS:IN POS:JJR POS:CC POS:JJR POS:NN POS:IN POS:NN POS:NN POS:. 
[sentNum: 44]<Annotation Id="6414" Type="Sentence" StartNode="6869" EndNode="7003">Value may also differ based on any individual patient (and physician) weighting of population estimates of benefits, harms, and costs.PreferredName:Numerical value SemanticType:[qnco] PreferredName:Individual SemanticType:[humn] PreferredName:Patient Base SemanticType:[qnco] PreferredName:Physicians SemanticType:[prog] PreferredName:Weight SemanticType:[qnco] PreferredName:geographic population SemanticType:[qnco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Financial cost SemanticType:[qnco] POS:NN POS:MD POS:RB POS:VB POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:NN POS:CC POS:NN POS:CD POS:NN POS:IN POS:NN POS:NNS POS:IN POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:. 
[sentNum: 45]<Annotation Id="6415" Type="Sentence" StartNode="7007" EndNode="7196">This article was reviewed and approved by the High Value Care Task Force, whose members are physicians trained in internal medicine and its subspecialties and experts in evidence synthesis. PreferredName:Article SemanticType:[inpr] PreferredName:Reviewed SemanticType:[qlco] PreferredName:Approved SemanticType:[qlco] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:care activity SemanticType:[acty] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:member SemanticType:[popg] PreferredName:Physicians SemanticType:[prog] PreferredName:Transportation Services - Train SemanticType:[mnob] PreferredName:Internal medicine physicians SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Synthesis SemanticType:[acty] POS:DT POS:NN POS:VBD POS:VBN POS:CC POS:VBN POS:IN POS:DT POS:JJ POS:NNP POS:NNP POS:NNP POS:NNP POS:, POS:WP$ POS:NNS POS:VBP POS:NNS POS:VBN POS:IN POS:JJ POS:NN POS:CC POS:PRP$ POS:NNS POS:CC POS:NNS POS:IN POS:NN POS:NN POS:. 
[sentNum: 46]<Annotation Id="6416" Type="Sentence" StartNode="7197" EndNode="7313">The Task Force developed the high-value care advice statements on the basis of a narrative review of the literature. PreferredName:Advisory Committees SemanticType:[gora] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:care activity SemanticType:[acty] PreferredName:Advice SemanticType:[hlca] PreferredName:Statement SemanticType:[idcn] PreferredName:Basis SemanticType:[phsu] PreferredName:Narration SemanticType:[socb] PreferredName:Review Literature SemanticType:[inpr] POS:DT POS:NNP POS:NNP POS:VBD POS:DT POS:JJ POS:NN POS:NN POS:NNS POS:IN POS:DT POS:NN POS:IN POS:DT POS:JJ POS:NN POS:IN POS:DT POS:NN POS:. 
[sentNum: 47]<Annotation Id="6417" Type="Sentence" StartNode="7314" EndNode="7401">At each conference call, all members declared all financial and nonfinancial interests. PreferredName:Conferences SemanticType:[hcpp] PreferredName:Precursor B-cell lymphoblastic leukemia SemanticType:[neop] PreferredName:member SemanticType:[popg] PreferredName:financial SemanticType:[qnco] PreferredName:Interested SemanticType:[menp] POS:IN POS:DT POS:NN POS:NN POS:, POS:DT POS:NNS POS:VBD POS:DT POS:JJ POS:CC POS:JJ POS:NNS POS:. 
[sentNum: 48]<Annotation Id="6418" Type="Sentence" StartNode="7402" EndNode="7455">The target audience for this paper is all clinicians. PreferredName:Target Audience SemanticType:[grup] PreferredName:Paper Authorization SemanticType:[idcn] PreferredName:Clinician SemanticType:[prog] POS:DT POS:NN POS:NN POS:IN POS:DT POS:NN POS:VBZ POS:DT POS:NNS POS:. 
[sentNum: 49]<Annotation Id="6419" Type="Sentence" StartNode="7456" EndNode="7524">The target patient population is average-risk, asymptomatic persons.PreferredName:Target Population SemanticType:[popg] PreferredName:Patients SemanticType:[podg] PreferredName:Average SemanticType:[qnco] PreferredName:Risk SemanticType:[qlco] PreferredName:Asymptomatic SemanticType:[fndg] PreferredName:Persons SemanticType:[popg] POS:DT POS:NN POS:NN POS:NN POS:VBZ POS:JJ POS:, POS:JJ POS:NNS POS:. 
[sentNum: 50]<Annotation Id="6420" Type="Sentence" StartNode="7528" EndNode="7535">RESULTSPreferredName:Result SemanticType:[ftcn] POS:NNS 
[sentNum: 51]<Annotation Id="6421" Type="Sentence" StartNode="7537" EndNode="7550">Breast Cancer PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:NN POS:NN 
[sentNum: 52]<Annotation Id="6422" Type="Sentence" StartNode="7553" EndNode="7810">On the basis of RCTs and corresponding modeling studies, all groups recommend mammography screening, or discussions about screening, at least every 2 years for women aged 40 to 74 years (Table 1 and Appendix Table 1, available at www.annals.org) (9, 12&#x2013;14). PreferredName:Basis SemanticType:[phsu] PreferredName:Modeling SemanticType:[inpr, resa] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Groups SemanticType:[idcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Discussion (procedure) SemanticType:[topp] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Less Than SemanticType:[inpr] PreferredName:Annual SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Table - furniture SemanticType:[mnob] PreferredName:Entire appendix SemanticType:[bpoc] PreferredName:Table - furniture SemanticType:[mnob] PreferredName:Availability of SemanticType:[ftcn] PreferredName:Internet SemanticType:[mnob] PreferredName:Professional Organization or Group SemanticType:[prog] POS:IN POS:DT POS:NN POS:IN POS:NNS POS:CC POS:JJ POS:NN POS:NNS POS:, POS:DT POS:NNS POS:VBP POS:NN POS:NN POS:, POS:CC POS:NNS POS:IN POS:NN POS:, POS:IN POS:JJS POS:DT POS:CD POS:NNS POS:IN POS:NNS POS:JJ POS:CD POS:TO POS:CD POS:NNS POS:RB POS:NNP POS:CD POS:CC POS:NNP POS:NNP POS:CD POS:, POS:JJ POS:IN POS:NN POS:. POS:NN POS:. POS:NN POS:CD POS:CD POS:CD POS:, POS:CD POS:CD POS:CD POS:NN POS:. 
[sentNum: 53]<Annotation Id="6423" Type="Sentence" StartNode="7811" EndNode="7958">No group recommends regular systematic breast selfexamination, magnetic resonance imaging (MRI), or tomosynthesis screening for average-risk women. PreferredName:Groups SemanticType:[idcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Regular SemanticType:[qlco] PreferredName:systematic SemanticType:[ftcn] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Average SemanticType:[qnco] PreferredName:Risk SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] POS:DT POS:NN POS:VBZ POS:JJ POS:JJ POS:NN POS:NN POS:, POS:JJ POS:NN POS:NN POS:CD POS:NNP POS:CD POS:, POS:CC POS:NN POS:NN POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 54]<Annotation Id="6424" Type="Sentence" StartNode="7959" EndNode="8061">Evidence is insufficient on the benefits of clinical breast examination beyond mammography alone (15). PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Insufficient (qualifier) SemanticType:[qlco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Clinical SemanticType:[qlco] PreferredName:Examination of breast SemanticType:[diap] PreferredName:Mammography SemanticType:[diap] PreferredName:alone - group size SemanticType:[grpa] POS:NN POS:VBZ POS:JJ POS:IN POS:DT POS:NNS POS:IN POS:JJ POS:NN POS:NN POS:IN POS:NN POS:RB POS:RB POS:CD POS:NN POS:. 
[sentNum: 55]<Annotation Id="6425" Type="Sentence" StartNode="8062" EndNode="8540">Reasons for not recommending more intensive strategies (such as annual screening, screening younger or older age groups, screening persons of any age with a life expectancy less than 10 years, and screening with more sensitive tests) include concerns that they would lead to few benefits but large increases in harms, such as falsepositive screening test results and overdiagnosis and overtreatment of lesions that would never have progressed to cause clinical problems (16&#x2013;20). PreferredName:Indication of (contextual qualifier) SemanticType:[idcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:More SemanticType:[ftcn] PreferredName:strategy SemanticType:[menp] PreferredName:annual screening SemanticType:[diap] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Young SemanticType:[tmco] PreferredName:Older Population SemanticType:[popg] PreferredName:Age SemanticType:[orga] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Persons SemanticType:[popg] PreferredName:Age SemanticType:[orga] PreferredName:In addition to SemanticType:[qlco] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:year SemanticType:[tmco] PreferredName:Screening Tests SemanticType:[hlca] PreferredName:Confidentiality - sensitive SemanticType:[idcn] PreferredName:Include (action) SemanticType:[acty] PreferredName:Concern SemanticType:[idcn] PreferredName:Dietary Lead SemanticType:[elii] PreferredName:Benefits SemanticType:[qnco] PreferredName:Large SemanticType:[qnco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Test Result SemanticType:[fndg] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Lesion SemanticType:[fndg] PreferredName:Never (frequency) SemanticType:[tmco] PreferredName:status - In progress SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:Science of Etiology SemanticType:[cnce] PreferredName:Clinical SemanticType:[qlco] PreferredName:Problems - What subject filter SemanticType:[idcn] POS:NNS POS:IN POS:RB POS:VBG POS:JJR POS:JJ POS:NNS POS:VBP POS:JJ POS:IN POS:JJ POS:NN POS:, POS:VBG POS:JJR POS:CC POS:JJR POS:NN POS:NNS POS:, POS:VBG POS:NNS POS:IN POS:DT POS:NN POS:IN POS:DT POS:NN POS:NN POS:JJR POS:IN POS:CD POS:NNS POS:, POS:CC POS:NN POS:IN POS:RBR POS:JJ POS:NNS POS:VBP POS:VBP POS:NNS POS:IN POS:PRP POS:MD POS:VB POS:TO POS:JJ POS:NNS POS:CC POS:JJ POS:NNS POS:IN POS:NNS POS:, POS:JJ POS:IN POS:JJ POS:JJ POS:NN POS:NNS POS:CC POS:NN POS:CC POS:NN POS:IN POS:NNS POS:WDT POS:MD POS:RB POS:VB POS:VBN POS:TO POS:VB POS:JJ POS:NNS POS:VBP POS:CD POS:CD POS:CD POS:NN POS:. 
[sentNum: 56]<Annotation Id="6426" Type="Sentence" StartNode="8541" EndNode="8590">Screening costs would also greatly increase (21).PreferredName:Disease Screening SemanticType:[diap] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Increase SemanticType:[ftcn] POS:VBG POS:NNS POS:MD POS:RB POS:RB POS:VB POS:CD POS:CD POS:NN POS:. 
[sentNum: 57]<Annotation Id="6427" Type="Sentence" StartNode="8594" EndNode="8812">High-value care advice 1: Clinicians should discuss the benefits and harms of screening mammography with average-risk women aged 40 to 49 years and order biennial mammography screening if an informed woman requests it.PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:care activity SemanticType:[acty] PreferredName:Advice SemanticType:[hlca] PreferredName:Clinician SemanticType:[prog] PreferredName:Benefits SemanticType:[qnco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Average SemanticType:[qnco] PreferredName:Risk SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Order (document) SemanticType:[inpr] PreferredName:Mammography SemanticType:[diap] PreferredName:Screening procedure SemanticType:[hlca] PreferredName:Informed SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Request - action SemanticType:[ftcn] POS:JJ POS:NN POS:NN POS:CD POS:: POS:NNS POS:MD POS:VB POS:DT POS:NNS POS:CC POS:NNS POS:IN POS:VBG POS:NN POS:IN POS:JJ POS:NNS POS:JJ POS:CD POS:TO POS:CD POS:NNS POS:CC POS:NN POS:JJ POS:NN POS:NN POS:IN POS:DT POS:VBN POS:NN POS:NNS POS:PRP POS:. 
[sentNum: 58]<Annotation Id="6428" Type="Sentence" StartNode="8816" EndNode="8943">High-value care advice 2: Clinicians should encourage biennial mammography screening in average-risk women aged 50 to 74 years.PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:care activity SemanticType:[acty] PreferredName:Advice SemanticType:[hlca] PreferredName:Clinician SemanticType:[prog] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Average SemanticType:[qnco] PreferredName:Risk SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] POS:JJ POS:NN POS:NN POS:CD POS:: POS:NNS POS:MD POS:VB POS:JJ POS:NN POS:NN POS:IN POS:JJ POS:NNS POS:JJ POS:CD POS:TO POS:CD POS:NNS POS:. 
[sentNum: 59]<Annotation Id="6429" Type="Sentence" StartNode="8947" EndNode="9156">High-value care advice 3: Clinicians should not screen average-risk women younger than 40 years or aged 75 years or older for breast cancer or screen women of any age with a life expectancy less than 10 years.PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:care activity SemanticType:[acty] PreferredName:Advice SemanticType:[hlca] PreferredName:Clinician SemanticType:[prog] PreferredName:Negation SemanticType:[ftcn] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Average SemanticType:[qnco] PreferredName:Risk SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Young SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Old age SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Age SemanticType:[orga] PreferredName:In addition to SemanticType:[qlco] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:year SemanticType:[tmco] POS:JJ POS:NN POS:NN POS:CD POS:: POS:NNS POS:MD POS:RB POS:VB POS:JJ POS:NNS POS:JJR POS:IN POS:CD POS:NNS POS:CC POS:JJ POS:CD POS:NNS POS:CC POS:JJR POS:IN POS:NN POS:NN POS:CC POS:NN POS:NNS POS:IN POS:DT POS:NN POS:IN POS:DT POS:NN POS:NN POS:JJR POS:IN POS:CD POS:NNS POS:. 
[sentNum: 60]<Annotation Id="6430" Type="Sentence" StartNode="9160" EndNode="9289">High-value care advice 4: Clinicians should not screen average-risk women of any age for breast cancer with MRI or tomosynthesis.PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:care activity SemanticType:[acty] PreferredName:Advice SemanticType:[hlca] PreferredName:Clinician SemanticType:[prog] PreferredName:Negation SemanticType:[ftcn] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Average SemanticType:[qnco] PreferredName:Risk SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Age SemanticType:[orga] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] POS:JJ POS:NN POS:NN POS:CD POS:: POS:NNS POS:MD POS:RB POS:VB POS:JJ POS:NNS POS:IN POS:DT POS:NN POS:IN POS:NN POS:NN POS:IN POS:NNP POS:CC POS:NN POS:. 
[sentNum: 61]<Annotation Id="6431" Type="Sentence" StartNode="9291" EndNode="9299">Table 1. PreferredName:Table - furniture SemanticType:[mnob] POS:NNP POS:CD POS:. 
[sentNum: 62]<Annotation Id="6432" Type="Sentence" StartNode="9300" EndNode="9363">High- and Low-Value Screening Strategies for 5 Types of Cancer*PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:strategy SemanticType:[menp] PreferredName:Type 5 SemanticType:[inpr] POS:JJ POS:CC POS:JJ POS:NN POS:VBG POS:NNS POS:IN POS:CD POS:NNS POS:IN POS:NN POS:SYM 
[sentNum: 63]<Annotation Id="6433" Type="Sentence" StartNode="9365" EndNode="9498">Least Intensive Recommended Cancer Screening Strategies (High Value)	Cancer Screening Strategies That Are Not Recommended (Low Value)PreferredName:Less Than SemanticType:[inpr] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:strategy SemanticType:[menp] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:strategy SemanticType:[menp] PreferredName:Negation SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] POS:NNP POS:NNP POS:NNP POS:NNP POS:NNP POS:NNS POS:VBP POS:JJ POS:NN POS:NN POS:NN POS:VBG POS:NNS POS:WDT POS:VBP POS:RB POS:VBN POS:NN POS:JJ POS:NN POS:NN 
[sentNum: 64]<Annotation Id="6434" Type="Sentence" StartNode="9500" EndNode="9644">Women aged 40&#x2013;49 y: Discuss benefits and harms with women in good health, and order screening with mammography every 2 y if a woman requests it. PreferredName:Woman SemanticType:[popg] PreferredName:Age SemanticType:[orga] PreferredName:/40 SemanticType:[tmco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Personal Satisfaction SemanticType:[fndg] PreferredName:Order (document) SemanticType:[inpr] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Integer +2 SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Request for SemanticType:[ftcn] POS:NNS POS:JJ POS:CD POS:CD POS:CD POS:NN POS:: POS:VB POS:NNS POS:CC POS:NNS POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:, POS:CC POS:NN POS:NN POS:IN POS:NN POS:DT POS:CD POS:NN POS:IN POS:DT POS:NN POS:NNS POS:PRP POS:. 
[sentNum: 65]<Annotation Id="6435" Type="Sentence" StartNode="9645" EndNode="9712">Women aged 50&#x2013;74 y in good health: Encourage mammography every 2 y.	PreferredName:Woman SemanticType:[popg] PreferredName:Age SemanticType:[orga] PreferredName:Personal Satisfaction SemanticType:[fndg] PreferredName:Mammography SemanticType:[diap] PreferredName:Integer +2 SemanticType:[qnco] POS:NNS POS:JJ POS:CD POS:CD POS:CD POS:NN POS:IN POS:JJ POS:NN POS:: POS:VB POS:NN POS:DT POS:CD POS:NN POS:. 
[sentNum: 66]<Annotation Id="6436" Type="Sentence" StartNode="9713" EndNode="9734">Women aged &lt;40 y or ?75PreferredName:Woman SemanticType:[popg] PreferredName:Age SemanticType:[orga] PreferredName:/40 SemanticType:[tmco] POS:NNS POS:JJ POS:JJR POS:CD POS:NN POS:CC POS:. 
[sentNum: 67]<Annotation Id="6437" Type="Sentence" StartNode="9734" EndNode="9827">75 y and women of any age not in good health and with a life expectancy &lt;10 y: Any screening. PreferredName:Woman SemanticType:[popg] PreferredName:Age SemanticType:[orga] PreferredName:Negation SemanticType:[ftcn] PreferredName:Personal Satisfaction SemanticType:[fndg] PreferredName:And SemanticType:[idcn] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:Disease Screening SemanticType:[diap] POS:CD POS:NN POS:CC POS:NNS POS:IN POS:DT POS:NN POS:RB POS:IN POS:JJ POS:NN POS:CC POS:IN POS:DT POS:NN POS:NN POS:JJR POS:CD POS:NN POS:: POS:DT POS:NN POS:. 
[sentNum: 68]<Annotation Id="6438" Type="Sentence" StartNode="9828" EndNode="9931">Women of any age: Annual mammography, MRI, tomosynthesis, or regular systematic breast self-examinationPreferredName:Woman SemanticType:[popg] PreferredName:Age SemanticType:[orga] PreferredName:Annual SemanticType:[tmco] PreferredName:Mammography SemanticType:[diap] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Regular SemanticType:[qlco] PreferredName:systematic SemanticType:[ftcn] PreferredName:Breast Self-Examination SemanticType:[diap] POS:NNS POS:IN POS:DT POS:NN POS:: POS:JJ POS:NN POS:, POS:NNP POS:, POS:NN POS:, POS:CC POS:JJ POS:JJ POS:NN POS:NN 
[sentNum: 69]<Annotation Id="6439" Type="Sentence" StartNode="9935" EndNode="10025">FUTURE DIRECTIONS: ENHANCING CANCER SCREENING VALUE BY REDUCING OVERLY INTENSIVE SCREENINGPreferredName:Future SemanticType:[tmco] PreferredName:Directions SemanticType:[spco] PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Reduced SemanticType:[qlco] POS:JJ POS:NNS POS:: POS:VBG POS:NNP POS:NNP POS:NNP POS:NNP POS:NNP POS:RB POS:JJ POS:NN 
[sentNum: 70]<Annotation Id="6440" Type="Sentence" StartNode="10027" EndNode="10185">An important step to improving cancer screening value is to increase implementation of underused strategies in which benefits clearly justify harms and costs. PreferredName:Increment SemanticType:[qnco] PreferredName:Improving (qualifier value) SemanticType:[qlco] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Numerical value SemanticType:[qnco] PreferredName:To SemanticType:[qlco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Implementation SemanticType:[acty] PreferredName:strategy SemanticType:[menp] PreferredName:Benefits SemanticType:[qnco] PreferredName:justify SemanticType:[ftcn] PreferredName:Financial cost SemanticType:[qnco] POS:DT POS:JJ POS:NN POS:TO POS:VBG POS:NN POS:NN POS:NN POS:VBZ POS:TO POS:VB POS:NN POS:IN POS:JJ POS:NNS POS:IN POS:WDT POS:NNS POS:RB POS:VBP POS:NNS POS:CC POS:NNS POS:. 
[sentNum: 71]<Annotation Id="6441" Type="Sentence" StartNode="10186" EndNode="10273">This is an important problem, especially in populations with inadequate access to care. PreferredName:Problem SemanticType:[fndg] PreferredName:Population Group SemanticType:[popg] PreferredName:Inadequate (qualifier) SemanticType:[qlco] PreferredName:Role Class - access SemanticType:[idcn] PreferredName:care activity SemanticType:[acty] POS:DT POS:VBZ POS:DT POS:JJ POS:NN POS:, POS:RB POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:TO POS:VB POS:. 
[sentNum: 72]<Annotation Id="6442" Type="Sentence" StartNode="10274" EndNode="10397">We list 6 key principles that could enhance future cancer screening value by reducing overly intensive screening (Table 2). PreferredName:List SemanticType:[cnce] PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Future SemanticType:[tmco] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Reduced SemanticType:[qlco] PreferredName:Table - furniture SemanticType:[mnob] POS:PRP POS:VBP POS:CD POS:JJ POS:NNS POS:WDT POS:MD POS:VB POS:JJ POS:NN POS:NN POS:NN POS:IN POS:VBG POS:RB POS:JJ POS:VBG POS:CD POS:NNP POS:CD POS:CD POS:. 
[sentNum: 73]<Annotation Id="6443" Type="Sentence" StartNode="10398" EndNode="10606">In Appendix Table 2 (available at www.annals.org), we provide the types of additional evidence needed before widespread implementation, as well as selected preliminary evidence that supports these principles. PreferredName:Entire appendix SemanticType:[bpoc] PreferredName:Table - furniture SemanticType:[mnob] PreferredName:Availability of SemanticType:[ftcn] PreferredName:Internet SemanticType:[mnob] PreferredName:Professional Organization or Group SemanticType:[prog] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Type - attribute SemanticType:[qlco] PreferredName:Additional SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Needs SemanticType:[qlco] PreferredName:Widespread SemanticType:[spco] PreferredName:Implementation SemanticType:[acty] PreferredName:Choose (action) SemanticType:[acty] PreferredName:Preliminary SemanticType:[tmco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Supportive assistance SemanticType:[cnce] POS:IN POS:NNP POS:NNP POS:CD POS:CD POS:JJ POS:IN POS:NN POS:. POS:NN POS:. POS:NN POS:NN POS:, POS:PRP POS:VBP POS:DT POS:NNS POS:IN POS:JJ POS:NN POS:VBN POS:IN POS:JJ POS:NN POS:, POS:RB POS:RB POS:IN POS:VBN POS:JJ POS:NN POS:IN POS:VBZ POS:DT POS:NNS POS:. 
[sentNum: 74]<Annotation Id="6444" Type="Sentence" StartNode="10607" EndNode="10794">The results of the presented studies should stimulate consideration for future research and implementation of strategies to enhance screening value by reducing overly intensive screening. PreferredName:research outcome SemanticType:[fndg] PreferredName:Presentation SemanticType:[idcn] PreferredName:consideration SemanticType:[fndg] PreferredName:Future SemanticType:[tmco] PreferredName:Research Activities SemanticType:[resa] PreferredName:Implementation SemanticType:[acty] PreferredName:strategy SemanticType:[menp] PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Reduced SemanticType:[qlco] POS:DT POS:NNS POS:IN POS:DT POS:VBN POS:NNS POS:MD POS:VB POS:NN POS:IN POS:JJ POS:NN POS:CC POS:NN POS:IN POS:NNS POS:TO POS:VB POS:JJ POS:NN POS:IN POS:VBG POS:RB POS:JJ POS:NN POS:. 
[sentNum: 75]<Annotation Id="6445" Type="Sentence" StartNode="10795" EndNode="10878">The identified studies are not based on a systematic search and are not definitive. PreferredName:Identified SemanticType:[qlco] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Negation SemanticType:[ftcn] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:systematic SemanticType:[ftcn] PreferredName:Search - action SemanticType:[acty] PreferredName:Negation SemanticType:[ftcn] PreferredName:Definitive SemanticType:[tmco] POS:DT POS:VBN POS:NNS POS:VBP POS:RB POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:CC POS:VBP POS:RB POS:JJ POS:. 
[sentNum: 76]<Annotation Id="6446" Type="Sentence" StartNode="10879" EndNode="10985">Findings are primarily based on single studies or modeling or cost analyses requiring several assumptions. PreferredName:Procedure findings:Finding:Point in time:^Patient:Narrative SemanticType:[clna] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Singular SemanticType:[qnco] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Modeling SemanticType:[inpr, resa] PreferredName:Cost Analysis SemanticType:[ocac] PreferredName:Numerous SemanticType:[qnco] POS:NNS POS:VBP POS:RB POS:VBN POS:IN POS:JJ POS:NNS POS:CC POS:NN POS:CC POS:NN POS:NNS POS:VBG POS:JJ POS:NNS POS:. 
[sentNum: 77]<Annotation Id="6447" Type="Sentence" StartNode="10986" EndNode="11063">Other suggestive evidence comes from subgroup results from randomized trials. PreferredName:Suggestive of SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Subgroup SemanticType:[clas] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Clinical Trials, Randomized SemanticType:[inpr, resa] POS:JJ POS:JJ POS:NN POS:VBZ POS:IN POS:NN POS:VBZ POS:IN POS:VBN POS:NNS POS:. 
[sentNum: 78]<Annotation Id="6448" Type="Sentence" StartNode="11064" EndNode="11251">Further research confirming these findings is needed before widespread implementation, but they may hold promise for future, higher-value strategies that involve less-intensive screening. PreferredName:Further SemanticType:[spco] PreferredName:Research Activities SemanticType:[resa] PreferredName:Confirmation SemanticType:[idcn] PreferredName:Procedure findings:Finding:Point in time:^Patient:Narrative SemanticType:[clna] PreferredName:Needs SemanticType:[qlco] PreferredName:Widespread SemanticType:[spco] PreferredName:Implementation SemanticType:[acty] PreferredName:Hold - dosing instruction fragment SemanticType:[idcn] PreferredName:promise SemanticType:[idcn] PreferredName:Future SemanticType:[tmco] PreferredName:High SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:strategy SemanticType:[menp] PreferredName:Smaller SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] POS:JJ POS:NN POS:VBG POS:DT POS:NNS POS:VBZ POS:VBN POS:IN POS:JJ POS:NN POS:, POS:CC POS:PRP POS:MD POS:VB POS:NN POS:IN POS:NN POS:, POS:JJ POS:NNS POS:WDT POS:VBP POS:JJ POS:NN POS:. 
[sentNum: 79]<Annotation Id="6449" Type="Sentence" StartNode="11252" EndNode="11401">Few studies considered by guideline developers or in our additional searches examined harms and costs to the same degree that they examined benefits. PreferredName:Few SemanticType:[qnco] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:consider SemanticType:[idcn] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:developers SemanticType:[medd] PreferredName:Additional SemanticType:[ftcn] PreferredName:Search - action SemanticType:[acty] PreferredName:Examined SemanticType:[fndg] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Same SemanticType:[qlco] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:Examined SemanticType:[fndg] PreferredName:Benefits SemanticType:[qnco] POS:JJ POS:NNS POS:VBN POS:IN POS:NN POS:NNS POS:CC POS:IN POS:PRP$ POS:JJ POS:NNS POS:VBN POS:NNS POS:CC POS:NNS POS:TO POS:DT POS:JJ POS:NN POS:IN POS:PRP POS:VBD POS:NNS POS:. 
[sentNum: 80]<Annotation Id="6450" Type="Sentence" StartNode="11402" EndNode="11541">Thus, few studies and corresponding guideline developers could directly assess the value of the screening strategy they were investigating.PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:developers SemanticType:[medd] PreferredName:Direct (qualifier) SemanticType:[qlco] PreferredName:Assessed SemanticType:[acty] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:strategy SemanticType:[menp] PreferredName:Investigates SemanticType:[ftcn] POS:RB POS:, POS:JJ POS:NNS POS:CC POS:JJ POS:NN POS:NNS POS:MD POS:RB POS:VB POS:DT POS:NN POS:IN POS:DT POS:NN POS:NN POS:PRP POS:VBD POS:VBG POS:. 
[sentNum: 81]<Annotation Id="6451" Type="Sentence" StartNode="11545" EndNode="11597">HOW COMMON IS OVERLY INTENSIVE, LOW-VALUE SCREENING?PreferredName:shared attribute SemanticType:[ftcn] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] POS:NNP POS:NNP POS:VBZ POS:RB POS:JJ POS:, POS:JJ POS:NN POS:. 
[sentNum: 82]<Annotation Id="6452" Type="Sentence" StartNode="11601" EndNode="11649">Overly intensive, low-value screening is common. PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:shared attribute SemanticType:[ftcn] POS:RB POS:JJ POS:, POS:JJ POS:NN POS:VBZ POS:JJ POS:. 
[sentNum: 83]<Annotation Id="6453" Type="Sentence" StartNode="11650" EndNode="11803">For example, 20% of women aged 30 to 39 years received a physician recommendation for mammography, and 23% to 35% in this age group had mammography (40). PreferredName:Example SemanticType:[cnce] PreferredName:Woman SemanticType:[popg] PreferredName:Age SemanticType:[orga] PreferredName:year SemanticType:[tmco] PreferredName:Receive SemanticType:[qlco] PreferredName:Physicians SemanticType:[prog] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Mammography SemanticType:[diap] PreferredName:Arabic numeral 23 SemanticType:[qnco] PreferredName:Human Age Group SemanticType:[aggp] PreferredName:Mammography SemanticType:[diap] PreferredName:/40 SemanticType:[tmco] POS:IN POS:NN POS:, POS:CD POS:NN POS:IN POS:NNS POS:JJ POS:CD POS:TO POS:CD POS:NNS POS:VBD POS:DT POS:NN POS:NN POS:IN POS:NN POS:, POS:CC POS:CD POS:NN POS:TO POS:CD POS:NN POS:IN POS:DT POS:NN POS:NN POS:VBD POS:NN POS:CD POS:CD POS:NN POS:. 
[sentNum: 84]<Annotation Id="6454" Type="Sentence" StartNode="11804" EndNode="11854">Most women having mammography receive it annually. PreferredName:Woman SemanticType:[popg] PreferredName:Mammography SemanticType:[diap] PreferredName:Receive SemanticType:[qlco] PreferredName:Annual SemanticType:[tmco] POS:JJS POS:NNS POS:VBG POS:NN POS:VBP POS:PRP POS:RB POS:. 
[sentNum: 85]<Annotation Id="6455" Type="Sentence" StartNode="11855" EndNode="12023">One third of surveyed primary care physicians screen with ultrasonography and MRI, in addition to mammography, in women who are not at increased risk for breast cancer. PreferredName:One SemanticType:[qnco] PreferredName:Third SemanticType:[qnco] PreferredName:Surveys SemanticType:[inpr] PreferredName:Primary Care Physicians SemanticType:[prog] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Ultrasonography SemanticType:[diap] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Mammography SemanticType:[diap] PreferredName:Woman SemanticType:[popg] PreferredName:Not Obtained SemanticType:[qlco] PreferredName:Risk SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:CD POS:NN POS:IN POS:VBN POS:JJ POS:NN POS:NNS POS:NN POS:IN POS:NN POS:CC POS:NNP POS:, POS:IN POS:NN POS:TO POS:NN POS:, POS:IN POS:NNS POS:WP POS:VBP POS:RB POS:IN POS:VBN POS:NN POS:IN POS:NN POS:NN POS:. 
[sentNum: 86]<Annotation Id="6456" Type="Sentence" StartNode="12024" EndNode="12118">Claims data demonstrate high use of screening MRI in women who are not at increased risk (41). PreferredName:Data SemanticType:[idcn] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Use of SemanticType:[ftcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Woman SemanticType:[popg] PreferredName:Not Obtained SemanticType:[qlco] PreferredName:Risk SemanticType:[qlco] POS:NNS POS:NNS POS:VBP POS:JJ POS:NN POS:IN POS:VBG POS:NNP POS:IN POS:NNS POS:WP POS:VBP POS:RB POS:IN POS:VBN POS:NN POS:NN POS:CD POS:NN POS:. 
[sentNum: 87]<Annotation Id="6457" Type="Sentence" StartNode="12119" EndNode="12233">Among women aged 80 years or older, cervical and breast cancer screening occurs in 38% and 50%, respectively (19). PreferredName:Woman SemanticType:[popg] PreferredName:Age SemanticType:[orga] PreferredName:year SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] PreferredName:Cervical SemanticType:[spco] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Occurrence SemanticType:[tmco] POS:IN POS:NNS POS:VBN POS:CD POS:NNS POS:CC POS:JJR POS:, POS:JJ POS:CC POS:NN POS:NN POS:NN POS:VBZ POS:IN POS:CD POS:NN POS:CC POS:CD POS:NN POS:, POS:RB POS:CD POS:CD POS:NN POS:. 
[sentNum: 88]<Annotation Id="6458" Type="Sentence" StartNode="12234" EndNode="12327">Cervical cancer screening is commonly done earlier and more frequently than recommended (42). PreferredName:early detection of cervical cancer SemanticType:[topp] PreferredName:Early SemanticType:[tmco] PreferredName:More SemanticType:[ftcn] PreferredName:Frequent SemanticType:[tmco] PreferredName:Recommendation SemanticType:[idcn] POS:JJ POS:NN POS:NN POS:VBZ POS:RB POS:VBN POS:JJR POS:CC POS:RBR POS:RB POS:IN POS:VBN POS:NN POS:CD POS:NN POS:. 
[sentNum: 89]<Annotation Id="6459" Type="Sentence" StartNode="12328" EndNode="12428">Nearly 70% of women without a cervix received a Pap test for cervical cancer screening in 2002 (43). PreferredName:Woman SemanticType:[popg] PreferredName:Cervix Uteri SemanticType:[bpoc] PreferredName:Receive SemanticType:[qlco] PreferredName:GLI3 wt Allele SemanticType:[gngm] PreferredName:Laboratory Procedures SemanticType:[lbpr] PreferredName:early detection of cervical cancer SemanticType:[topp] POS:RB POS:CD POS:NN POS:IN POS:NNS POS:IN POS:DT POS:NN POS:VBD POS:DT POS:NN POS:NN POS:IN POS:JJ POS:NN POS:NN POS:IN POS:CD POS:CD POS:CD POS:NN POS:. 
[sentNum: 90]<Annotation Id="6460" Type="Sentence" StartNode="12429" EndNode="12500">An estimated 1.2 million U.S. women have ovarian cancer screening (44). PreferredName:Estimated SemanticType:[qnco] PreferredName:Million SemanticType:[qnco] PreferredName:United States SemanticType:[geoa] PreferredName:Woman SemanticType:[popg] PreferredName:ovarian cancer screening SemanticType:[topp] POS:DT POS:VBN POS:CD POS:. POS:CD POS:CD POS:NNP POS:. POS:NN POS:. POS:NNS POS:VBP POS:JJ POS:NN POS:NN POS:CD POS:CD POS:NN POS:. 
[sentNum: 91]<Annotation Id="6461" Type="Sentence" StartNode="12501" EndNode="12669">More than 40% of responding internists and nearly all gynecologists report performing annual pelvic examinations for ovarian or other gynecologic cancer screening (45).PreferredName:More SemanticType:[ftcn] PreferredName:/40 SemanticType:[tmco] PreferredName:Internist SemanticType:[prog] PreferredName:Gynecologist SemanticType:[prog] PreferredName:Report (document) SemanticType:[inpr] PreferredName:Performed SemanticType:[ftcn] PreferredName:Health Checkup SemanticType:[topp] PreferredName:Pelvis SemanticType:[blor] PreferredName:Ovaro- SemanticType:[bpoc] PreferredName:Malignant Female Reproductive System Neoplasm SemanticType:[neop] PreferredName:Aspects of disease screening SemanticType:[ftcn] POS:JJR POS:IN POS:CD POS:NN POS:IN POS:VBG POS:NNS POS:CC POS:RB POS:DT POS:NNS POS:VBP POS:VBG POS:JJ POS:JJ POS:NNS POS:IN POS:JJ POS:CC POS:JJ POS:JJ POS:NN POS:NN POS:CD POS:CD POS:NN POS:. 
[sentNum: 92]<Annotation Id="6462" Type="Sentence" StartNode="12673" EndNode="12730">Inappropriate colorectal cancer screening is also common. PreferredName:Inappropriate SemanticType:[qlco] PreferredName:early detection of colorectal cancer SemanticType:[topp] PreferredName:shared attribute SemanticType:[ftcn] POS:JJ POS:JJ POS:NN POS:NN POS:VBZ POS:RB POS:JJ POS:. 
[sentNum: 93]<Annotation Id="6463" Type="Sentence" StartNode="12731" EndNode="12904">Sixty percent of adults had colonoscopies more frequently than guidelines recommend, and screening often occurs in adults with life expectancies of 5 years or less (46&#x2013; 48). PreferredName:Percent (qualifier value) SemanticType:[qnco] PreferredName:Adult SemanticType:[aggp] PreferredName:colonoscopy SemanticType:[diap, topp] PreferredName:Frequent SemanticType:[tmco] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Frequent SemanticType:[tmco] PreferredName:Occurrence SemanticType:[tmco] PreferredName:Adult SemanticType:[aggp] PreferredName:In addition to SemanticType:[qlco] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:year SemanticType:[tmco] PreferredName:Less Than SemanticType:[inpr] POS:CD POS:NN POS:IN POS:NNS POS:VBD POS:NNS POS:RBR POS:RB POS:IN POS:NNS POS:VB POS:, POS:CC POS:NN POS:RB POS:VBZ POS:IN POS:NNS POS:IN POS:NN POS:NNS POS:IN POS:CD POS:NNS POS:CC POS:JJR POS:CD POS:CD POS:NN POS:CD POS:NN POS:. 
[sentNum: 94]<Annotation Id="6464" Type="Sentence" StartNode="12905" EndNode="13004">Among persons having an FOBT screening test, 8% had a negative result less than 1 year before (49). PreferredName:Persons SemanticType:[popg] PreferredName:Fecal occult blood test SemanticType:[lbpr] PreferredName:Screening Tests SemanticType:[hlca] PreferredName:Negative SemanticType:[qlco] PreferredName:Result SemanticType:[ftcn] PreferredName:per year SemanticType:[tmco] POS:IN POS:NNS POS:VBG POS:DT POS:NN POS:NN POS:NN POS:, POS:CD POS:NN POS:VBD POS:DT POS:JJ POS:NN POS:JJR POS:IN POS:CD POS:NN POS:IN POS:CD POS:CD POS:NN POS:. 
[sentNum: 95]<Annotation Id="6465" Type="Sentence" StartNode="13005" EndNode="13097">One third of men having PSA testing do not recall being told that the test was ordered (50). PreferredName:One SemanticType:[qnco] PreferredName:Third SemanticType:[qnco] PreferredName:Male population group SemanticType:[popg] PreferredName:Testing SemanticType:[ftcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Recall:-:Point in time:^Patient:- SemanticType:[clna] PreferredName:Laboratory Procedures SemanticType:[lbpr] PreferredName:Order (arrangement) SemanticType:[qlco] POS:CD POS:NN POS:IN POS:NNS POS:VBG POS:NN POS:NN POS:VBP POS:RB POS:VB POS:VBG POS:VBD POS:IN POS:DT POS:NN POS:VBD POS:VBN POS:RB POS:CD POS:CD POS:. 
[sentNum: 96]<Annotation Id="6466" Type="Sentence" StartNode="13098" EndNode="13225">Most persons having PSA testing received annual cancer screening, and one half of men aged 75 to 79 years had recent screening. PreferredName:Persons SemanticType:[popg] PreferredName:Testing SemanticType:[ftcn] PreferredName:Receive SemanticType:[qlco] PreferredName:annual screening SemanticType:[diap] PreferredName:Malignant Neoplasms SemanticType:[neop] PreferredName:One SemanticType:[qnco] PreferredName:Half SemanticType:[qnco] PreferredName:Male population group SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Recent SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] POS:JJS POS:NNS POS:VBG POS:NN POS:NN POS:VBD POS:JJ POS:NN POS:NN POS:, POS:CC POS:CD POS:NN POS:IN POS:NNS POS:JJ POS:CD POS:TO POS:CD POS:NNS POS:VBD POS:JJ POS:NN POS:. 
[sentNum: 97]<Annotation Id="6467" Type="Sentence" StartNode="13226" EndNode="13343">More than 50% of men and women older than 75 years report that their physicians continue to recommend screening (51).PreferredName:More SemanticType:[ftcn] PreferredName:Male population group SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:Old SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Report (document) SemanticType:[inpr] PreferredName:Physicians SemanticType:[prog] PreferredName:Continuous SemanticType:[idcn] PreferredName:To SemanticType:[qlco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] POS:JJR POS:IN POS:CD POS:NN POS:IN POS:NNS POS:CC POS:NNS POS:JJR POS:IN POS:CD POS:NNS POS:VBP POS:IN POS:PRP$ POS:NNS POS:VBP POS:TO POS:VB POS:JJ POS:NN POS:CD POS:NN POS:. 
[sentNum: 98]<Annotation Id="6468" Type="Sentence" StartNode="13347" EndNode="13357">DiscussionPreferredName:Discussion (procedure) SemanticType:[topp] POS:NN 
[sentNum: 99]<Annotation Id="6469" Type="Sentence" StartNode="13359" EndNode="13441">The ACP strongly encourages considering value in making health care decisions (4). PreferredName:Cerebral Palsy, Ataxic, Autosomal Recessive SemanticType:[dsyn] PreferredName:consider SemanticType:[idcn] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Healthcare decision making SemanticType:[inbe] POS:DT POS:NNP POS:RB POS:VBZ POS:VBG POS:NN POS:IN POS:VBG POS:NN POS:NN POS:NNS POS:VBP POS:CD POS:CD POS:. 
[sentNum: 100]<Annotation Id="6470" Type="Sentence" StartNode="13442" EndNode="13623">Our growing appreciation of the problems of overly intensive, low-value care, including unjustifiable harms and costs, should lead us to consider value in many areas of health care. PreferredName:Appreciation SemanticType:[cnce] PreferredName:Problems - What subject filter SemanticType:[idcn] PreferredName:Specialty Type - Intensive care SemanticType:[bmod] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Cost aspects SemanticType:[qnco] PreferredName:Dietary Lead SemanticType:[elii] PreferredName:To SemanticType:[qlco] PreferredName:consider SemanticType:[idcn] PreferredName:Numerical value SemanticType:[qnco] PreferredName:health care area SemanticType:[ocdi] POS:PRP$ POS:VBG POS:NN POS:IN POS:DT POS:NNS POS:IN POS:RB POS:JJ POS:, POS:JJ POS:NN POS:, POS:VBG POS:JJ POS:NNS POS:CC POS:NNS POS:, POS:MD POS:VB POS:PRP POS:TO POS:VB POS:NN POS:IN POS:JJ POS:NNS POS:IN POS:NN POS:NN POS:. 
[sentNum: 101]<Annotation Id="6471" Type="Sentence" StartNode="13624" EndNode="13657">Cancer screening is no exception.PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Exception - Property or Attribute SemanticType:[cnce] POS:NN POS:NN POS:VBZ POS:DT POS:NN POS:. 
[sentNum: 102]<Annotation Id="6472" Type="Sentence" StartNode="13661" EndNode="13856">We summarized cancer screening recommendations for 5 common types of cancer, finding much agreement about acceptable minimal screening strategies and not recommending overly intensive strategies. PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Recommendation SemanticType:[idcn] PreferredName:shared attribute SemanticType:[ftcn] PreferredName:Type 5 SemanticType:[inpr] PreferredName:Experimental Finding SemanticType:[fndg] PreferredName:Agreement SemanticType:[socb] PreferredName:Acceptable SemanticType:[qlco] PreferredName:Minimum SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:strategy SemanticType:[menp] PreferredName:Negation SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:strategy SemanticType:[menp] POS:PRP POS:VBD POS:NN POS:JJ POS:NNS POS:IN POS:CD POS:JJ POS:NNS POS:IN POS:NN POS:, POS:VBG POS:JJ POS:NN POS:IN POS:JJ POS:JJ POS:NN POS:NNS POS:CC POS:RB POS:VBG POS:RB POS:JJ POS:NNS POS:. 
[sentNum: 103]<Annotation Id="6473" Type="Sentence" StartNode="13857" EndNode="13993">Guideline groups are increasingly considering value in terms of balancing benefits and harms in making cancer screening recommendations. PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Groups SemanticType:[idcn] PreferredName:consider SemanticType:[idcn] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Term (lexical) SemanticType:[idcn] PreferredName:Able to balance SemanticType:[fndg] PreferredName:Benefits SemanticType:[qnco] PreferredName:Make - Instruction Imperative SemanticType:[ftcn] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Recommendation SemanticType:[idcn] POS:NN POS:NNS POS:VBP POS:RB POS:VBG POS:NN POS:IN POS:NNS POS:IN POS:VBG POS:NNS POS:CC POS:NNS POS:IN POS:VBG POS:NN POS:JJ POS:NNS POS:. 
[sentNum: 104]<Annotation Id="6474" Type="Sentence" StartNode="13994" EndNode="14118">This value consideration is associated with greater agreement on recommendations for screening for specific types of cancer. PreferredName:Numerical value SemanticType:[qnco] PreferredName:consideration SemanticType:[fndg] PreferredName:Associated with SemanticType:[qlco] PreferredName:Largest SemanticType:[qnco] PreferredName:Agreement SemanticType:[socb] PreferredName:Upon - dosing instruction fragment SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Specific qualifier value SemanticType:[qlco] PreferredName:Type - attribute SemanticType:[qlco] PreferredName:Malignant Neoplasms SemanticType:[neop] POS:DT POS:NN POS:NN POS:VBZ POS:VBN POS:IN POS:JJR POS:NN POS:IN POS:NNS POS:IN POS:VBG POS:IN POS:JJ POS:NNS POS:IN POS:NN POS:. 
[sentNum: 105]<Annotation Id="6475" Type="Sentence" StartNode="14119" EndNode="14357">Although disagreement remains in some areas, such as annual (9) versus biennial (14) mammography screening for breast cancer, it is possible to develop a list of generally agreed-on, less intensive strategies that we define as high value. PreferredName:Discord SemanticType:[socb] PreferredName:Area SemanticType:[spco] PreferredName:Annual SemanticType:[tmco] PreferredName:Mammography SemanticType:[diap] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Possible SemanticType:[qlco] PreferredName:List SemanticType:[cnce] PreferredName:Agree SemanticType:[inpr] PreferredName:Smaller SemanticType:[qlco] PreferredName:strategy SemanticType:[menp] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] POS:IN POS:NN POS:VBZ POS:IN POS:DT POS:NNS POS:, POS:JJ POS:IN POS:JJ POS:NN POS:CD POS:CD POS:CC POS:JJ POS:NN POS:CD POS:CD POS:NN POS:NN POS:IN POS:NN POS:NN POS:, POS:PRP POS:VBZ POS:JJ POS:TO POS:VB POS:DT POS:NN POS:IN POS:RB POS:JJ POS:, POS:RBR POS:JJ POS:NNS POS:IN POS:PRP POS:VBP POS:RB POS:JJ POS:NN POS:. 
[sentNum: 106]<Annotation Id="6476" Type="Sentence" StartNode="14358" EndNode="14416">This consensus should be seen as a remarkable achievement.PreferredName:Consensus SemanticType:[socb] PreferredName:Seen SemanticType:[qlco] PreferredName:Achievement SemanticType:[bhvr] POS:DT POS:NN POS:MD POS:VB POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:. 
[sentNum: 107]<Annotation Id="6477" Type="Sentence" StartNode="14420" EndNode="14599">In addition to generally acceptable, high-value screening strategies, we found much agreement about recommending against or not recommending overly intensive, low-value screening. PreferredName:Acceptable SemanticType:[qlco] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:strategy SemanticType:[menp] PreferredName:Present SemanticType:[qnco] PreferredName:Agreement SemanticType:[socb] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] POS:IN POS:NN POS:TO POS:RB POS:JJ POS:, POS:JJ POS:NN POS:NNS POS:, POS:PRP POS:VBD POS:JJ POS:NN POS:IN POS:VBG POS:IN POS:CC POS:RB POS:VBG POS:RB POS:JJ POS:, POS:JJ POS:NN POS:. 
[sentNum: 108]<Annotation Id="6478" Type="Sentence" StartNode="14600" EndNode="14735">Recommendations have trended toward less-intensive screening and may foreshadow further discussion about screening intensity and value. PreferredName:Recommendation SemanticType:[idcn] PreferredName:trend SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Further SemanticType:[spco] PreferredName:Discussion (procedure) SemanticType:[topp] PreferredName:Disease Screening SemanticType:[diap] PreferredName:With intensity SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] POS:NNS POS:VBP POS:VBN POS:IN POS:JJ POS:NN POS:CC POS:MD POS:VB POS:JJ POS:NN POS:IN POS:VBG POS:NN POS:CC POS:NN POS:. 
[sentNum: 109]<Annotation Id="6479" Type="Sentence" StartNode="14736" EndNode="14916">We believe that this trend enhances screening value, chiefly by forgoing the small incremental benefits of more intensive screening as not being justified by the increase in harms. PreferredName:trend SemanticType:[tmco] PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Small SemanticType:[qnco] PreferredName:Increment SemanticType:[qnco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Negation SemanticType:[ftcn] PreferredName:justify SemanticType:[ftcn] PreferredName:Increase SemanticType:[ftcn] POS:PRP POS:VBP POS:IN POS:DT POS:NN POS:VBZ POS:JJ POS:NN POS:, POS:RB POS:IN POS:VBG POS:DT POS:JJ POS:JJ POS:NNS POS:IN POS:JJR POS:JJ POS:NN POS:IN POS:RB POS:VBG POS:VBN POS:IN POS:DT POS:NN POS:IN POS:NNS POS:. 
[sentNum: 110]<Annotation Id="6480" Type="Sentence" StartNode="14917" EndNode="15087">Although these organizations do not make recommendations based on financial costs, less-intensive, high-value screening is less expensive than overly intensive screening. PreferredName:Organization administrative structures SemanticType:[orgt] PreferredName:Negation SemanticType:[ftcn] PreferredName:Make - Instruction Imperative SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Less Than SemanticType:[inpr] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Less Than SemanticType:[inpr] PreferredName:expense SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] POS:IN POS:DT POS:NNS POS:VBP POS:RB POS:VB POS:NNS POS:VBN POS:IN POS:JJ POS:NNS POS:, POS:JJ POS:, POS:JJ POS:NN POS:VBZ POS:RBR POS:JJ POS:IN POS:RB POS:JJ POS:NN POS:. 
[sentNum: 111]<Annotation Id="6481" Type="Sentence" StartNode="15088" EndNode="15167">We also found evidence that overly intensive and thus low-value care is common. PreferredName:Present SemanticType:[qnco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:care activity SemanticType:[acty] PreferredName:shared attribute SemanticType:[ftcn] POS:PRP POS:RB POS:VBD POS:NN POS:IN POS:RB POS:JJ POS:CC POS:RB POS:JJ POS:NN POS:VBZ POS:JJ POS:. 
[sentNum: 112]<Annotation Id="6482" Type="Sentence" StartNode="15168" EndNode="15282">In addition, underutilization of high-value care exists, especially among persons with limited health care access. PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:care activity SemanticType:[acty] PreferredName:Exist SemanticType:[cnce] PreferredName:Persons SemanticType:[popg] PreferredName:Limited (extensiveness) SemanticType:[ftcn] PreferredName:Health Services Accessibility SemanticType:[qlco] POS:IN POS:NN POS:, POS:NN POS:IN POS:JJ POS:NN POS:VBZ POS:, POS:RB POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:NN POS:NN POS:. 
[sentNum: 113]<Annotation Id="6483" Type="Sentence" StartNode="15283" EndNode="15458">Thus, clinicians can markedly improve cancer screening value by adhering to the widely agreed-on, high- and low-value strategies recommended by the High Value Care Task Force.PreferredName:Clinician SemanticType:[prog] PreferredName:Massive SemanticType:[qlco] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Immobile SemanticType:[fndg] PreferredName:Agree SemanticType:[inpr] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:strategy SemanticType:[menp] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:care activity SemanticType:[acty] PreferredName:Advisory Committees SemanticType:[gora] POS:RB POS:, POS:NNS POS:MD POS:RB POS:VB POS:NN POS:NN POS:NN POS:IN POS:JJ POS:TO POS:DT POS:RB POS:JJ POS:, POS:JJ POS:CC POS:JJ POS:NNS POS:VBN POS:IN POS:DT POS:JJ POS:NNP POS:NNP POS:NNP POS:NNP POS:. 
[sentNum: 114]<Annotation Id="6484" Type="Sentence" StartNode="15462" EndNode="15570">Further enhancing value may be possible through implementation of less rather than more intensive screening. PreferredName:Further SemanticType:[spco] PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Possible SemanticType:[qlco] PreferredName:Implementation SemanticType:[acty] PreferredName:More SemanticType:[ftcn] PreferredName:Screening procedure SemanticType:[hlca] POS:RB POS:VBG POS:NN POS:MD POS:VB POS:JJ POS:IN POS:NN POS:IN POS:JJR POS:RB POS:IN POS:JJR POS:JJ POS:NN POS:. 
[sentNum: 115]<Annotation Id="6485" Type="Sentence" StartNode="15571" EndNode="15785">We provided preliminary evidence and a value framework suggesting additional strategies that could enhance value through less intensive screening for clinicians, researchers, policymakers, and patients to consider. PreferredName:Providing (action) SemanticType:[acty] PreferredName:Preliminary SemanticType:[tmco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Numerical value SemanticType:[qnco] PreferredName:suggestion SemanticType:[idcn] PreferredName:Additional SemanticType:[ftcn] PreferredName:strategy SemanticType:[menp] PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Screening procedure SemanticType:[hlca] PreferredName:Clinician SemanticType:[prog] PreferredName:Research Personnel SemanticType:[prog] PreferredName:Patients SemanticType:[podg] PreferredName:consider SemanticType:[idcn] POS:PRP POS:VBD POS:JJ POS:NN POS:CC POS:DT POS:NN POS:NN POS:VBG POS:JJ POS:NNS POS:WDT POS:MD POS:VB POS:NN POS:IN POS:JJR POS:JJ POS:NN POS:IN POS:NNS POS:, POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:TO POS:VB POS:. 
[sentNum: 116]<Annotation Id="6486" Type="Sentence" StartNode="15786" EndNode="15973">However, implementation will require additional research consistently demonstrating that lessintensive screening leads to little loss in benefits and larger reductions in harms and costs. PreferredName:Implementation SemanticType:[acty] PreferredName:Additional SemanticType:[ftcn] PreferredName:Research Activities SemanticType:[resa] PreferredName:Screening procedure SemanticType:[hlca] PreferredName:Dietary Lead SemanticType:[elii] PreferredName:Small SemanticType:[qnco] PreferredName:Loss SemanticType:[qnco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Largest SemanticType:[qnco] PreferredName:Harm Reduction SemanticType:[topp] PreferredName:Financial cost SemanticType:[qnco] POS:RB POS:, POS:NN POS:MD POS:VB POS:JJ POS:NN POS:RB POS:VBG POS:IN POS:JJ POS:NN POS:VBZ POS:TO POS:JJ POS:NN POS:IN POS:NNS POS:CC POS:JJR POS:NNS POS:IN POS:NNS POS:CC POS:NNS POS:. 
[sentNum: 117]<Annotation Id="6487" Type="Sentence" StartNode="15974" EndNode="16085">Guideline groups and researchers need to better clarify which screening strategies represent high or low value. PreferredName:Guidelines SemanticType:[inpr] PreferredName:Population Group SemanticType:[popg] PreferredName:Research Personnel SemanticType:[prog] PreferredName:Needs SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Better SemanticType:[qlco] PreferredName:Clarify SemanticType:[acty] PreferredName:Screening procedure SemanticType:[hlca] PreferredName:strategy SemanticType:[menp] PreferredName:Representation (action) SemanticType:[acty] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] POS:NN POS:NNS POS:CC POS:NNS POS:VBP POS:TO POS:RBR POS:VB POS:WDT POS:NN POS:NNS POS:VBP POS:JJ POS:CC POS:JJ POS:NN POS:. 
[sentNum: 118]<Annotation Id="6488" Type="Sentence" StartNode="16086" EndNode="16276">Guideline developers can help clinicians determine the value of screening strategies by searching for evidence about health benefits, harms, and costs and then carefully analyzing tradeoffs. PreferredName:Guidelines SemanticType:[inpr] PreferredName:developers SemanticType:[medd] PreferredName:Helping Behavior SemanticType:[socb] PreferredName:Clinician SemanticType:[prog] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Screening procedure SemanticType:[hlca] PreferredName:strategy SemanticType:[menp] PreferredName:Belarus SemanticType:[geoa] PreferredName:Search - action SemanticType:[acty] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Health Benefits SemanticType:[qnco] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Then SemanticType:[tmco] POS:NN POS:NNS POS:MD POS:VB POS:NNS POS:VB POS:DT POS:NN POS:IN POS:NN POS:NNS POS:IN POS:VBG POS:IN POS:NN POS:IN POS:NN POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:CC POS:RB POS:RB POS:VBG POS:NNS POS:. 
[sentNum: 119]<Annotation Id="6489" Type="Sentence" StartNode="16277" EndNode="16419">For some organizations, this would be a departure because they may not adequately consider evidence about harms and often do not assess costs. PreferredName:Organization administrative structures SemanticType:[orgt] PreferredName:Departure - action SemanticType:[acty] PreferredName:Negation SemanticType:[ftcn] PreferredName:consider SemanticType:[idcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Frequent SemanticType:[tmco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Assessed SemanticType:[acty] PreferredName:Financial cost SemanticType:[qnco] POS:IN POS:DT POS:NNS POS:, POS:DT POS:MD POS:VB POS:DT POS:NN POS:IN POS:PRP POS:MD POS:RB POS:RB POS:VB POS:NN POS:IN POS:NNS POS:CC POS:RB POS:VBP POS:RB POS:VB POS:NNS POS:. 
[sentNum: 120]<Annotation Id="6490" Type="Sentence" StartNode="16420" EndNode="16570">To improve the value of screening (and health care in general), harms and costs should be considered equally with benefits to explicitly assess value. PreferredName:To SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Screening procedure SemanticType:[hlca] PreferredName:health care in general SemanticType:[inpr] PreferredName:Financial cost SemanticType:[qnco] PreferredName:consider SemanticType:[idcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Assessed SemanticType:[acty] PreferredName:Numerical value SemanticType:[qnco] POS:TO POS:VB POS:DT POS:NN POS:IN POS:VBG POS:NN POS:CC POS:NN POS:NN POS:IN POS:JJ POS:NN POS:, POS:NNS POS:CC POS:NNS POS:MD POS:VB POS:VBN POS:RB POS:IN POS:NNS POS:TO POS:RB POS:VB POS:NN POS:. 
[sentNum: 121]<Annotation Id="6491" Type="Sentence" StartNode="16571" EndNode="16710">Clinicians should pay special attention to transparent recommendations from organizations that are rigorous in making these determinations.PreferredName:Clinician SemanticType:[prog] PreferredName:pay SemanticType:[qnco] PreferredName:Special SemanticType:[qlco] PreferredName:Attention SemanticType:[menp] PreferredName:Translucent SemanticType:[qlco] PreferredName:Advice SemanticType:[hlca] PreferredName:Organization administrative structures SemanticType:[orgt] PreferredName:Rigor - Temperature-associated observation SemanticType:[sosy] PreferredName:Make - Instruction Imperative SemanticType:[ftcn] PreferredName:Adjudication SemanticType:[gora] POS:NNS POS:MD POS:VB POS:JJ POS:NN POS:TO POS:JJ POS:NNS POS:IN POS:NNS POS:WDT POS:VBP POS:JJ POS:IN POS:VBG POS:DT POS:NNS POS:. 
[sentNum: 122]<Annotation Id="6492" Type="Sentence" StartNode="16714" EndNode="16812">Researchers play an essential role in determining and enhancing the value of screening strategies. PreferredName:Research Personnel SemanticType:[prog] PreferredName:Does play SemanticType:[fndg] PreferredName:Essential SemanticType:[qlco] PreferredName:Social Role SemanticType:[socb] PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:strategy SemanticType:[menp] POS:NNS POS:VBP POS:DT POS:JJ POS:NN POS:IN POS:VBG POS:CC POS:VBG POS:DT POS:NN POS:IN POS:NN POS:NNS POS:. 
[sentNum: 123]<Annotation Id="6493" Type="Sentence" StartNode="16813" EndNode="16931">For persons with repeated negative test results, research should consider the additional value of continued screening. PreferredName:Preposition For SemanticType:[qlco] PreferredName:Persons SemanticType:[popg] PreferredName:Repeat SemanticType:[ftcn] PreferredName:Negative Test Result SemanticType:[fndg] PreferredName:Research Activities SemanticType:[resa] PreferredName:consider SemanticType:[idcn] PreferredName:Additional SemanticType:[ftcn] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Continuous SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] POS:IN POS:NNS POS:IN POS:VBN POS:JJ POS:NN POS:NNS POS:, POS:NN POS:MD POS:VB POS:DT POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:. 
[sentNum: 124]<Annotation Id="6494" Type="Sentence" StartNode="16932" EndNode="17169">Research should also consider how much benefit would be lost and how much harms and costs would be reduced by screening less frequently; using a higher test threshold to define abnormality; or screening a smaller, higher-risk population. PreferredName:Research Activities SemanticType:[resa] PreferredName:consider SemanticType:[idcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Lost SemanticType:[ftcn] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Reduced SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Frequent SemanticType:[tmco] PreferredName:Use of SemanticType:[ftcn] PreferredName:High SemanticType:[qlco] PreferredName:Laboratory Procedures SemanticType:[lbpr] PreferredName:Threshold SemanticType:[qlco] PreferredName:Abnormality SemanticType:[fndg] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Small SemanticType:[qnco] PreferredName:High Risk Populations SemanticType:[popg] POS:NNP POS:MD POS:RB POS:VB POS:WRB POS:JJ POS:NN POS:MD POS:VB POS:VBN POS:CC POS:WRB POS:JJ POS:NNS POS:CC POS:NNS POS:MD POS:VB POS:VBN POS:IN POS:VBG POS:RBR POS:RB POS:: POS:VBG POS:DT POS:JJR POS:NN POS:NN POS:TO POS:VB POS:NN POS:: POS:CC POS:VBG POS:DT POS:JJR POS:, POS:JJ POS:NN POS:. 
[sentNum: 125]<Annotation Id="6495" Type="Sentence" StartNode="17170" EndNode="17329">It would be difficult to consider these questions under a &#x201c;maximum cancer detection&#x201d; framework, but they become priority questions under a value framework (2). PreferredName:Difficult SemanticType:[qlco] PreferredName:consider SemanticType:[idcn] PreferredName:Theses SemanticType:[inpr] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Maximum Value Derivation Technique SemanticType:[qnco] PreferredName:Cancer Detection SemanticType:[hlca] PreferredName:Priority SemanticType:[tmco] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Integer +2 SemanticType:[qnco] POS:PRP POS:MD POS:VB POS:JJ POS:TO POS:VB POS:DT POS:NNS POS:IN POS:DT POS:NN POS:NN POS:NN POS:NN POS:CD POS:NN POS:, POS:CC POS:PRP POS:VBP POS:NN POS:NNS POS:IN POS:DT POS:NN POS:NN POS:NN POS:CD POS:NN POS:. 
[sentNum: 126]<Annotation Id="6496" Type="Sentence" StartNode="17330" EndNode="17532">Research must focus on the consequences of the full screening cascade, including a better understanding of what constitutes &#x201c;overdiagnosed cancer&#x201d; and how to reduce overdiagnosis and overtreatment (52). PreferredName:Research Activities SemanticType:[resa] PreferredName:Has focus SemanticType:[ftcn] PreferredName:Consequence of SemanticType:[ftcn] PreferredName:Full SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Cascade Device Component SemanticType:[mnob] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Better SemanticType:[qlco] PreferredName:Comprehension SemanticType:[menp] PreferredName:Malignant Neoplasms SemanticType:[neop] PreferredName:overdiagnosis SemanticType:[fndg] POS:NNP POS:MD POS:VB POS:IN POS:DT POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:NN POS:, POS:VBG POS:DT POS:JJR POS:NN POS:IN POS:WP POS:VBZ POS:NN POS:JJ POS:NN POS:NN POS:CC POS:WRB POS:TO POS:VB POS:NN POS:CC POS:NN POS:CD POS:CD POS:NN POS:. 
[sentNum: 127]<Annotation Id="6497" Type="Sentence" StartNode="17533" EndNode="17730">It should also focus on approaches clinicians can use to communicate the benefits, harms, and costs of screening to their patients and society, including ways of incorporating the concept of value.PreferredName:Has focus SemanticType:[ftcn] PreferredName:Approach SemanticType:[spco] PreferredName:Clinician SemanticType:[prog] PreferredName:utilization qualifier SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:Does communicate SemanticType:[fndg] PreferredName:Benefits SemanticType:[qnco] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Patients SemanticType:[podg] PreferredName:Societies SemanticType:[orgt] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:concept SemanticType:[idcn] PreferredName:Numerical value SemanticType:[qnco] POS:PRP POS:MD POS:RB POS:VB POS:IN POS:NNS POS:NNS POS:MD POS:VB POS:TO POS:VB POS:DT POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:IN POS:VBG POS:TO POS:PRP$ POS:NNS POS:CC POS:NN POS:, POS:VBG POS:NNS POS:IN POS:VBG POS:DT POS:NN POS:IN POS:NN POS:. 
[sentNum: 128]<Annotation Id="6498" Type="Sentence" StartNode="17734" EndNode="17839">Considering screening through the lens of value could change discussions between clinicians and patients. PreferredName:consider SemanticType:[idcn] PreferredName:Screening procedure SemanticType:[hlca] PreferredName:Lens (device) SemanticType:[medd] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Changing SemanticType:[ftcn] PreferredName:Discussion (procedure) SemanticType:[topp] PreferredName:Clinician SemanticType:[prog] PreferredName:Patients SemanticType:[podg] POS:VBG POS:NN POS:IN POS:DT POS:NN POS:IN POS:NN POS:MD POS:VB POS:NNS POS:IN POS:NNS POS:CC POS:NNS POS:. 
[sentNum: 129]<Annotation Id="6499" Type="Sentence" StartNode="17840" EndNode="18122">Rather than assuming that all screening is highvalue, clinicians might start a conversation with the understanding that it always involves tradeoffs between benefits versus harms and costs and that some patients may reasonably decide that they would prefer less intensive screening. PreferredName:Screening procedure SemanticType:[hlca] PreferredName:Clinician SemanticType:[prog] PreferredName:Beginning SemanticType:[tmco] PreferredName:Conversation SemanticType:[socb] PreferredName:Comprehension SemanticType:[menp] PreferredName:Always (frequency) SemanticType:[tmco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Patients SemanticType:[podg] PreferredName:Less Than SemanticType:[inpr] PreferredName:Screening procedure SemanticType:[hlca] POS:RB POS:IN POS:VBG POS:IN POS:DT POS:NN POS:VBZ POS:JJ POS:, POS:NNS POS:MD POS:VB POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:PRP POS:RB POS:VBZ POS:NNS POS:IN POS:NNS POS:CC POS:NNS POS:CC POS:NNS POS:CC POS:IN POS:DT POS:NNS POS:MD POS:RB POS:VB POS:IN POS:PRP POS:MD POS:VB POS:JJR POS:JJ POS:NN POS:. 
[sentNum: 130]<Annotation Id="6500" Type="Sentence" StartNode="18123" EndNode="18350">Further, considering the patient's situation and own weighting of benefits and harms may lead him or her to conclude that cancer screening is not the highest priority and that there may be other more pressing issues to discuss.PreferredName:Further SemanticType:[spco] PreferredName:consider SemanticType:[idcn] PreferredName:Patients SemanticType:[podg] PreferredName:Importance Weight SemanticType:[idcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Dietary Lead SemanticType:[elii] PreferredName:To SemanticType:[qlco] PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Negation SemanticType:[ftcn] PreferredName:High priority SemanticType:[tmco] PreferredName:More SemanticType:[ftcn] PreferredName:Problem SemanticType:[fndg] POS:RB POS:, POS:VBG POS:DT POS:NN POS:POS POS:NN POS:CC POS:JJ POS:NN POS:IN POS:NNS POS:CC POS:NNS POS:MD POS:VB POS:PRP POS:CC POS:PRP$ POS:TO POS:VB POS:IN POS:NN POS:NN POS:VBZ POS:RB POS:DT POS:JJS POS:NN POS:CC POS:IN POS:EX POS:MD POS:VB POS:JJ POS:RBR POS:VBG POS:NNS POS:TO POS:VB POS:. 
[sentNum: 131]<Annotation Id="6501" Type="Sentence" StartNode="18354" EndNode="18461">In conclusion, we advise clinicians to consider value when discussing cancer screening with their patients. PreferredName:Conclusion SemanticType:[idcn] PreferredName:Clinician SemanticType:[prog] PreferredName:consider SemanticType:[idcn] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Patients SemanticType:[podg] POS:IN POS:NN POS:, POS:PRP POS:VBP POS:NNS POS:TO POS:VB POS:NN POS:WRB POS:VBG POS:NN POS:NN POS:IN POS:PRP$ POS:NNS POS:. 
[sentNum: 132]<Annotation Id="6502" Type="Sentence" StartNode="18462" EndNode="18637">Implementation of high-value strategies and avoidance of the overly intensive, low-value strategies that we outlined as widely agreed-on would increase cancer screening value. PreferredName:Implementation SemanticType:[acty] PreferredName:High SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:strategy SemanticType:[menp] PreferredName:Avoidance SemanticType:[menp] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:strategy SemanticType:[menp] PreferredName:Agree SemanticType:[inpr] PreferredName:Increase SemanticType:[ftcn] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Numerical value SemanticType:[qnco] POS:NN POS:IN POS:JJ POS:NNS POS:CC POS:NN POS:IN POS:DT POS:RB POS:JJ POS:, POS:JJ POS:NNS POS:IN POS:PRP POS:VBD POS:IN POS:RB POS:JJ POS:MD POS:VB POS:NN POS:NN POS:NN POS:. 
[sentNum: 133]<Annotation Id="6503" Type="Sentence" StartNode="18638" EndNode="18775">In addition, an emphasis on enhancing value by decreasing harms and costs while preserving most benefits may resonate with many patients. PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Decreasing SemanticType:[qlco] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Preserving SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Patients SemanticType:[podg] POS:IN POS:NN POS:, POS:DT POS:NN POS:IN POS:VBG POS:NN POS:IN POS:VBG POS:NNS POS:CC POS:NNS POS:IN POS:VBG POS:RBS POS:NNS POS:MD POS:VB POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 134]<Annotation Id="6504" Type="Sentence" StartNode="18776" EndNode="18872">Low-value screening can result from strategies that are either too low or too high in intensity. PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:strategy SemanticType:[menp] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:High SemanticType:[qlco] PreferredName:With intensity SemanticType:[qlco] POS:JJ POS:NN POS:MD POS:VB POS:IN POS:NNS POS:WDT POS:VBP POS:RB POS:RB POS:JJ POS:CC POS:RB POS:JJ POS:IN POS:NN POS:. 
[sentNum: 135]<Annotation Id="6505" Type="Sentence" StartNode="18873" EndNode="18958">We have focused on the problem of overly intensive strategies that lead to low value. PreferredName:Focal SemanticType:[spco] PreferredName:Problem SemanticType:[fndg] PreferredName:strategy SemanticType:[menp] PreferredName:Lead SemanticType:[elii, hops] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] POS:PRP POS:VBP POS:VBN POS:IN POS:DT POS:NN POS:IN POS:RB POS:JJ POS:NNS POS:WDT POS:VBP POS:TO POS:JJ POS:NN POS:. 
[sentNum: 136]<Annotation Id="6506" Type="Sentence" StartNode="18959" EndNode="19166">Reducing overly intensive, lowvalue screening would not only reduce screening harms and costs but also release time and resources to increase intensity among underserved groups, thus further improving value.PreferredName:Reduced SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Negation SemanticType:[ftcn] PreferredName:Singular SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Discharge (release) SemanticType:[hlca] PreferredName:Time SemanticType:[tmco] PreferredName:Resources SemanticType:[idcn] PreferredName:Increase SemanticType:[ftcn] PreferredName:With intensity SemanticType:[qlco] PreferredName:Populations, Underserved SemanticType:[popg] PreferredName:Further SemanticType:[spco] PreferredName:Improving (qualifier value) SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] POS:VBG POS:RB POS:JJ POS:, POS:JJ POS:NN POS:MD POS:RB POS:RB POS:VB POS:VBG POS:NNS POS:CC POS:NNS POS:CC POS:RB POS:VBP POS:NN POS:CC POS:NNS POS:TO POS:VB POS:NN POS:IN POS:JJ POS:NNS POS:, POS:RB POS:RB POS:VBG POS:NN POS:. 
